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Abstract
A robust simian-human immunodeficiency virus (SHIV)-rhesus macaque (RM) model of HIV latency and
cure is needed. Our group has generated >20 SHIVs encoding various HIV-1 Envs of interest, including
transmitted/founder (TF) Envs. TF SHIVs encode a substitution at Env residue 375 that confers
consistent early viral kinetics in RM, although longitudinal kinetics are more variable. Further, TF SHIVs
have not been evaluated for their suitability for HIV latency and cure research. For my first aim, I evaluated
two promising TF SHIVs, SHIV.191859 and SHIV.CH848, for their viral kinetics and persistence during
suppressive combination antiretroviral therapy (cART). These SHIVs demonstrated consistent early viral
kinetics, rapid viremic suppression following cART initiation, and viral rebound following treatment
interruption, mirroring HIV infection. Reservoir analyses of both peripheral and lymphoid cells revealed
systemic virus dissemination and establishment of viral reservoirs that persisted despite cART. The viral
dynamics and reservoir biology of SHIV.191859, and to a lesser extent SHIV.CH848, suggest that these TF
SHIVs are promising reagents for a SHIV model of HIV latency and cure. For my second aim, I endeavored
to engineer an enhanced clone of SHIV.CH505, a TF SHIV that is of significant interest to the HIV field but
replicates variably over time in RM. A common signature of mutations that arose in 10
SHIV.CH505-infected RM with high VLs was identified via single genome sequencing. To assess the
contribution of signature mutations to viral fitness in vitro, a library of clones containing signature
mutations alone or in combination was generated; these clones demonstrated modestly enhanced
replication in isolation and significantly enhanced replication in combination compared to the parental
(TF) virus. 8 combination clones that exhibited desirable characteristics in vitro were tested in vivo. A
clone containing 5 mutations compared to the TF, 5MA, dramatically outcompeted all other viruses,
including the TF, when tested in vivo in 7 RM. TZM-bl neutralization assays revealed that 5MA retained a
native Env conformation. Further, 5MA demonstrated significantly enhanced entry into target cells
compared to the TF. We have generated a minimally adapted SHIV.CH505 with enhanced replication that
has broad applications for HIV research in RM.
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ABSTRACT
DEVELOPMENT AND VALIDATION OF NOVEL TRANSMITTED/FOUNDER SHIVS
FOR HIV PERSISTENCE AND CURE RESEARCH
Anya Bauer
Katharine Bar

A robust simian-human immunodeficiency virus (SHIV)-rhesus macaque (RM)
model of HIV latency and cure is needed. Our group has generated >20 SHIVs encoding
various HIV-1 Envs of interest, including transmitted/founder (TF) Envs. TF SHIVs
encode a substitution at Env residue 375 that confers consistent early viral kinetics in
RM, although longitudinal kinetics are more variable. Further, TF SHIVs have not been
evaluated for their suitability for HIV latency and cure research. For my first aim, I
evaluated two promising TF SHIVs, SHIV.191859 and SHIV.CH848, for their viral
kinetics and persistence during suppressive combination antiretroviral therapy (cART).
These SHIVs demonstrated consistent early viral kinetics, rapid viremic suppression
following cART initiation, and viral rebound following treatment interruption, mirroring
HIV infection. Reservoir analyses of both peripheral and lymphoid cells revealed
systemic virus dissemination and establishment of viral reservoirs that persisted despite
cART. The viral dynamics and reservoir biology of SHIV.191859, and to a lesser extent
SHIV.CH848, suggest that these TF SHIVs are promising reagents for a SHIV model of
HIV latency and cure. For my second aim, I endeavored to engineer an enhanced clone
of SHIV.CH505, a TF SHIV that is of significant interest to the HIV field but replicates
variably over time in RM. A common signature of mutations that arose in 10
SHIV.CH505-infected RM with high VLs was identified via single genome sequencing.
iv

To assess the contribution of signature mutations to viral fitness in vitro, a library of
clones containing signature mutations alone or in combination was generated; these
clones demonstrated modestly enhanced replication in isolation and significantly
enhanced replication in combination compared to the parental (TF) virus. 8 combination
clones that exhibited desirable characteristics in vitro were tested in vivo. A clone
containing 5 mutations compared to the TF, 5MA, dramatically outcompeted all other
viruses, including the TF, when tested in vivo in 7 RM. TZM-bl neutralization assays
revealed that 5MA retained a native Env conformation. Further, 5MA demonstrated
significantly enhanced entry into target cells compared to the TF. We have generated a
minimally adapted SHIV.CH505 with enhanced replication that has broad applications
for HIV research in RM.
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CHAPTER 1: INTRODUCTION
Origins of HIV-1
Acquired immunodeficiency syndrome (AIDS) was first described in CDC’s
Morbidity and Mortality Weekly Report in 1981: young, recently healthy men were dying
of opportunistic infections and unusual cancers due to an unknown cause 1. A mere 2
years later, Françoise Barré-Sinoussi, Luc Montagnier and colleagues isolated what
would become known as the human immunodeficiency virus (HIV) and identified it as the
causative agent of AIDS2,3. HIV/AIDS would go on to become one of the defining public
health crises of the late 20th century, with over 77 million infections and over 35 million
AIDS-related deaths reported as of 20184. HIV-1 group M, which is the most pathogenic
subtype and is responsible for the majority of the global pandemic, began replicating in
humans in approximately 1931,5 following cross-species transmission from a simianimmunodeficiency virus (SIV)-infected chimpanzee6. There have been 3 further crossspecies transmissions from chimpanzees and gorillas, resulting in 3 additional
genetically distinct HIV-1 groups: N, O, and P7. HIV-2, which is less pathogenic and is
more geographically restricted to West Africa 8, originated from a SIV-infected sooty
mangabey9.

The biology of HIV-1 infection
HIV-1 is a member of the Lentivirus genus in the Retroviridae family3; viruses in
this genus are characterized by long incubation periods leading to progressive
illnesses10. HIV-1 is a single-stranded, positive sense, enveloped RNA virus, with a
1

genome that is ~9.8 kB in length. The HIV-1 genome consists of 9 open reading frames
that code for 15 proteins. Gag, Pol, and Env are the 3 main proteins produced during
early viral transcription10. Env, which is the sole protein expressed on the surface of the
virion, mediates entry into target cells and fusion of the viral and host cell membranes.
Gag mediates a number of virion assembly and maturation processes, including
synthesis of the viral capsid, which houses 2 copies of the HIV-1 RNA genome10. The
cleavage of the Pol precursor by the viral enzyme protease results in the formation of 3
enzymes that are critical for infection of the host cell: reverse transcriptase, which is
used to transcribe the HIV-1 genome after fusion and entry, protease, and integrase,
which enables integration of the HIV-1 provirus into the host cell genome.
2 regulatory proteins play important roles for viral replication: Tat, which activates
viral gene transcription and Rev, which plays a crucial role in nuclear export of viral RNA
to the cytoplasm and is essential for regulating viral protein expression11. 4 additional
proteins, Vpu, Vpr, Vif, and Nef, are accessory proteins that aid in viral immune evasion
and/or mediate proper virus assembly and export10.
Env is synthesized as a 160 kD protein that is then cleaved by Furin, a hostderived protease, to form the gp120 Env ectodomain and the gp41
transmembrane/endomain12. Following cleavage of gp160 Env, the gp41 and gp120
subunits become non-covalently associated, forming an Env trimer consisting of 3 gp120
and 3 gp41 domains12. Upon binding to the host receptor CD4, which is expressed on
CD4+ T cells as well as other immune cells, including macrophages13, Env undergoes a
conformational change to initiate fusion with the host membrane12. Following CD4
binding, Env is able to bind to the host co-receptor, CCR5 or CXCR4, which triggers a
2

second conformational change, enabling fusion of the virus and host cell membranes
and injection of the viral genome into the host cytoplasm12. After entry into the target cell
is complete, the RNA genome located in the viral capsid protein, p24, is uncoated and
reverse-transcribed by reverse transcriptase10. The resultant full-length viral doublestranded DNA, now called a provirus, is integrated into the host chromosome by
integrase, which enables the cell to remain infected for the duration of its lifetime10.

HIV-1 transmission and viral kinetics
HIV is transmissible via sexual, perinatal, and parenteral routes; in adults, HIV-1
is predominantly acquired sexually14. A study of over 100 donor-host transmission pairs
found that in ~80% of heterosexual individuals and 60% of men who have sex with men
(MSM), infection is initiated by a single virus15. This finding implies that there is a low
multiplicity of infection based on the assumption that there is limited and random
diversification in the recipient during acute infection as a direct result of a stringent
genetic bottleneck during transmission15. Factors influencing the selection of the
transmitted/founder, or TF virus in the recipient are not completely understood, but
include preferential tropism for the CCR5 viral co-receptor and modestly enriched Env
content16. A recent report identified a signature of interferon-beta resistance in
transmitted/founder isolates17.
Following transmission, HIV-1 rapidly disseminates throughout the body, leading to
the saturation of target CD4+ cells in the peripheral blood and infection of CD4+ cells in
various lymphoid tissues, leading to peak viral loads (VL) of 106 – 108 copies/ml, or
3

c/ml18. The VL in most people living with HIV (PLWH) decreases to 102 – 105 c/ml
following the exhaustion of activated target cells during peak infection and the onset of
adaptive immune responses such as CD8 T cells and antibodies18; this decreased postpeak VL is known as the viral set point. If combination antiretroviral therapy (cART) is
not initiated, PLWH will develop significant CD4 T cell depletion and succumb to
opportunistic AIDS-associated infections within a median of 10 years19.

HIV-1 genetic diversity and epidemiology
The virus population in PLWH rapidly undergoes diversification due to the errorprone reverse-transcriptase, which has an error rate of approximately 3.7x10-4
mutations/nucleotide20. This high error rate, in conjunction with the short half-life of an
infected cell (~1 day)21,22 results in diversification of the virus population on the order of
1% per year in PLWH15. As a result, HIV variants that that are resistant to host immune
pressures, such as CD8 T cells23 and antibodies24,25 as well as antiviral agents26, can
easily be selected for, leading to rapid and complete viral escape. As described earlier,
innate immune responses have been shown to exert selective pressure on the virus
population at the transmission stage17, while adaptive immune responses begin to exert
significant selective pressure on the virus population as early as 1.5-4 weeks postinfection (WPI) in PLWH27,28. The resultant within-patient diversity, which increases with
each successive year of infection, has led to >5% interpatient diversity in pol29 and 2535% interpatient diversity in env across all HIV-1 isolates16.
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HIV-1 group M disproportionately affects individuals in developing countries; the
burden of disease is highest in sub-Saharan Africa4. Group M is further subdivided into
subtypes or clades based on genetic diversity. Subtype B viruses, which comprise ~10%
of the global total, are found primarily in the Americas, Western Europe, and Australia30.
Early HIV-1 research focused on subtype B viruses with near exclusivity, leading to a
relative dearth of information on other HIV-1 subtypes until fairly recently despite their
increased prevalence; this issue was compounded by the fact that countries with
predominantly clade B infections had earlier access to cART 31. Subtype C viruses, which
comprise 50% of the global total, are most commonly found in Eastern and Southern
Africa31. Subtype D viruses comprise 2.5% of the global total and are endemic to
Eastern Africa30. Infection with a subtype D virus is associated with faster disease
progression and a relatively rapid viral co-receptor switch from CCR5 to CXCR4, which
facilitates the infection and depletion of broader subsets of CD4-expressing T cells,
including naïve T cells, and often emerges concomitant with progression to AIDS30,32.
The relationship between subtype and rate of disease progression seems to be less
clear in other subtypes31. Multiple studies suggest that efficiency of various transmission
types (mother-to-child, intravenous, and sexual) are variable among HIV-1 clades31.
Thus, the extensive diversity and associated variation in viral characteristics across HIV1 clades significantly complicate efforts to produce HIV-1 vaccines and therapeutics that
are effective against all viruses circulating globally31.

5

HIV-1 latency and persistence
In 1996, the introduction of combination anti-retroviral therapy (cART), which
durably suppresses viremia to <400 c/ml and leads to immune cell preservation and
reconstitution in most individuals led to a significant decline in morbidity and mortality in
the HIV+ population33. The introduction of integrase inhibitors in 2007 led to a further
increase in the percentage of PLWH who achieve sustained virologic suppression. cART
containing an integrase inhibitor leads to an exponential decline in plasma viremia to
less than 50 c/ml within 2 months of cART initiation in most individuals34, resulting in
significantly decreased morbidity and mortality in the HIV+ population 35. Common
standard-of-care cART regimens prescribed to PLWH often include a combination of 2
nucleotide reverse transcriptase inhibitors and an integrase inhibitor36, although other
effective regimens are available. If cART-mediated viral suppression is durably
maintained, CD4 T cell depletion and progression to AIDS can be prevented. As a result,
in today’s era of effective cART, PLWH have a life expectancy that approaches that of
the general population37.
However, cART has several limitations: serious adverse effects, such as
diabetes, kidney dysfunction, and accelerated cardiovascular disease, have been
reported in a subset of patients on cART36. Further, lifelong adherence is required to
prevent progression to AIDS, as discontinuation of cART in the setting of an analytical
treatment interruption, or ATI, leads to viremic rebound in 85% of individuals within 4
weeks and almost all patients within 12 weeks post-ATI38,39. This systemic rebound
originates from the HIV-1 latent reservoir, which is comprised of a population of longlived infected cells in PBMC and lymphoid tissues that persist indefinitely40. Studies of
6

peripheral blood have suggested that low-level viremia (~1 c/ml) occurs throughout the
course of cART administration and cannot be reduced by further cART intensification 41.
The viral variants contributing to low-level viremia on cART, however, do not show
evidence of genetic diversification or acquisition of novel drug resistance mutations42,
implying that they result from constant, low-level reactivation of infected cells.
There are numerous methods available to assess the kinetics of viral decay in
various reservoirs upon initiation of cART. As described earlier, cART initiation is
associated with an exponential decrease in plasma virus, leading to an undetectable VL
(<50 c/ml) in most patients within 2 months of cART initiation. This decrease in plasma
VL is accompanied by modest (~1-2 log10) decreases in cell-associated viral DNA (caDNA) and viral RNA (ca-RNA) measurements, which reflect, at minimum, the clearance
of plasma virus, productively infected activated T cells with a short half-life (~2 days),
resting CD4 T cells with unintegrated virus, and likely shorter-lived effector cells21,22. CaDNA remains readily detectable in PLWH despite long-term suppressive cART,
indicating that the HIV-1 reservoir is relatively stable on cART and has a slow decay rate
on the order of months to years39. This stable or very slow decay rate reflects the
maintenance of longer lived cellular reservoirs, such as resting memory CD4 T cells
(Tcm), which have a half-life of months to years and are known to comprise a large
portion of the latent reservoir, along with effector memory T cells (Tem)43,44. Modeling
studies suggest that more than 60 years of cART treatment alone would be required to
achieve sustained viremic remission upon ATI, otherwise known as a “functional cure”40.
Thus, the HIV-1 latent reservoir presents a currently insurmountable barrier to HIV-1
cure.
7

The mechanisms that facilitate HIV-1 reservoir seeding and maintenance are not
completely understood, underscoring the need for validated animal models to elucidate
mechanisms of HIV-1 reservoir formation and persistence. Recent studies have
identified one major contributor to reservoir homeostasis: clonal expansion45, or the
continuous proliferation of Tcm and Tem that harbor HIV proviruses. Further, integration
site and sequencing analyses have revealed that the viruses in these expanded clones
have identical sequences as well as integration sites46, and thus are presumed to derive
from a single latently infected cell. HIV-1 expanded clones have been shown to be
extremely long-lived and proliferate due to several mechanisms, including antigen-driven
expansion, homeostatic proliferation, and integration site-driven cellular proliferation 46.
Upon ATI, viruses originating from genetically distinct virus lineages begin
replicating systemically in PLWH within the first week of rebound, indicating that
numerous non-identical virus-infected cells reactivate to contribute to recrudescent
viremia upon treatment interruption 47–50. Recrudescent viremia results from the
reactivation of distinct cells in both blood and lymphoid tissue compartments, supporting
a multifocal model of rebound50. Further, current latency assays have not been able to
predict which virus populations will contribute to recrudescent viremia upon ATI 51, which
can be considered a major barrier to developing effective HIV-1 cure strategies.

The advent of broadly neutralizing antibodies (bNAbs)
Env is the only viral protein that is able to be targeted by host, or autologous
neutralizing antibody responses due its location on the surface of the virion 12. Circulating
8

HIV-1 variants, however, have been adapted to effectively evade autologous antibody
responses using several mechanisms, including conformational masking of key epitopes
via N-linked glycosylation and extensive sequence variation in Env as described earlier,
enabling rapid escape24. The sensitivity of Envs to autologous neutralizing antibody
responses can generally be divided into several classes: Tier 1 Envs are unusually
sensitive to autologous and heterologous, or non-host neutralizing antibody responses,
Tier 2 Envs are more resistant, and Tier 3 Envs are most resistant52. Nearly all TF
viruses exhibit Tier 2 and 3 neutralization resistance, thereby presenting an obstacle to
development of both effective autologous antibody responses and vaccines52.
Recent scientific advances have identified bNAbs, or antibodies with potent and
broad specificity against diverse HIV isolates, in a subset of chronically infected
individuals53. Isolated bNAbs potently neutralized over 90% of viruses when tested in
vitro against a panel broadly representative of global isolates53,54. When administered
prophylactically, bNAbs were shown to confer protection against infection in a nonhuman primate (NHP) model of HIV infection.55 Further, bNAbs, when administered in
tandem with cART in multiple NHP studies, were shown to significantly delay viral
rebound compared to a control group 56,57. Next-generation vaccine design holds promise
for the elicitation of bNAbs in humans, as studying Env-antibody coevolution in an HIV+
individual that has developed bNAbs could serve as a blueprint for the design of
effective immunogens. BNAbs that have been identified thus far target various
conserved epitopes on Env, including the CD4 binding site, the membrane-proximal
external region, the trimer apex, and variable loop 3, which enables Env to bind the viral
co-receptors CCR5 and CXCR453.
9

Multiple studies assessing the efficacy of monoclonal bNAbs in suppressing
viremia following ATI have demonstrated a significant delay in time to rebound in
PLWH58,47. Trials assessing the efficacy of bNAbs in combination for this application are
in process. On this basis, various clinical trials evaluating the efficacy of next-generation
bNAbs for viral suppression in place of cART initiation and for HIV-1 prevention in
newborns and constantly exposed individuals are ongoing59, underscoring the promise
of this novel class of HIV-1 biologics.

Non-human primate models of HIV infection: SIVmac
NHP models for HIV-1 infection have played an integral role in understanding
transmission, immunopathogenesis, and evaluating prophylactic and therapeutic
interventions60. The Indian-origin rhesus macaque (RM) is the most commonly used
NHP model, although cynomolgus macaques and Chinese-origin RM are also used in
HIV-1 research60. Infection of Indian-origin RM with a macaque-adapted SIV (SIVmac)
leads to viral kinetics and immunopathogenesis similar to HIV-1 infection. The clinical
hallmarks of untreated HIV-1 infection, however, are greatly accelerated in the SIVmac
model, as untreated animals typically progress to AIDS within ~1 year post infection.61
This accelerated model of pathogenesis and disease progression makes SIVmac an
attractive reagent for certain NHP studies.
Many insights have been gained from studies of SIVmac-infected NHP, including
the identification of memory CD4 T cells as the main viral target in peripheral blood and
lymphoid tissues62 as well as identification of host factors that influence peak and set
10

point viremia63. SIVmac-infected RM, however, typically require more than 4 months of
cART administration to achieve durable virus suppression,60,64 in contrast to the 2 month
timeframe needed for most PLWH receiving current standard-of-care cART regimens34.
An additional difference between the SIVmac-NHP model and HIV-1 infection is
that set point VL in infected animals average around 10 6 c/ml, which is 1-2 log10-fold
higher than in HIV-1 infection65. This increased set point VL is likely attributable to some
combination of more severe immune dysregulation, microbial translocation, chronic
inflammation, and/or infection of cellular subsets in comparison to HIV-1 infection63.
Further, there are important structural differences between SIVmac and HIV-1 Envs. The
SIVmac239 and HXB2 Envs, which are considered to be representative of all SIVmac
and HIV-1 isolates, respectively, are 50% divergent, thus limiting the translatability of
studies that evaluate Env-targeting agents, such as vaccines and bNAbs66. Nonetheless,
SIVmac is considered to be the most robust NHP model for HIV-1 infection by many
investigators, as a plethora of well-powered studies show reproducible VL kinetics and
associated immunopathogenesis in large cohorts of outbred RM.

Non-human primate models of HIV infection: a brief history of SHIVs
An alternative and widely used NHP model of HIV-1 infection is the chimeric
simian-human immunodeficiency virus (SHIV)-macaque model. SHIVs encode an HIV-1
envelope glycoprotein (Env) within the background of macaque-adapted simian
immunodeficiency virus (SIVmac) structural and regulatory elements. SHIVs have wideranging applications, including studies of HIV-1 reservoir biology and pathogenesis, and
11

are the most directly suitable NHP model for evaluating HIV-1 Env-targeting agents such
as bNAbs67 and vaccines.
The first SHIV, 89.6, was generated by Sodroski and colleagues in 199667. SHIV
89.6 encodes a dual-tropic clade B Env. This virus was initially non-pathogenic in rhesus
macaques; virus acquisition resulted in non-persistent infection as assessed by plasma
VL, minimal CD4 T cell depletion, and lack of progression to AIDS. Serial passage, or
transfer of blood and/or tissues from an infected animal to a naïve animal, resulted in a
pathogenic viral swarm, termed 89.6P, after several sequential transfers. Serial passage
is based upon the idea that virus adaptation will occur given enough time and enough
exposures to various target hosts, leading to augmented virulence. 89.6P reliably elicited
CD4 T cell depletion and progression to AIDS in infected RM. After 3 passages, a
particularly virulent viral swarm, 89.6P3, was created, from which an infectious molecular
clone, KB9, was isolated. Subsequent studies identified several changes in the Env
amino acid (AA) sequence that were associated with the enhanced pathogenicity of
89.6P3/KB9; a follow up report identified increased fusogenicity and affinity for CCR5 as
the factors responsible for the increased virulence of KB968.
Several issues, however, quickly emerged with the use of SHIV 89.6. First, the
relentless CD4 T cell depletion in RM within weeks of inoculation, on account of the dual
tropism of the 89.6 Env, diverged greatly from the disease course typical of HIV-1
infection. In HIV-1 infection, co-receptor switch typically only occurs after years of
infection and does not occur in all PLWH67,69. In addition, TF viruses are overwhelmingly
CCR5-tropic15, limiting the extent to which SHIV 89.6 recapitulates HIV-1 infection in
individuals who have not progressed to AIDS. Further, preclinical studies that evaluated
12

myriad vaccines, including DNA vaccines, peptides, proteins, inactivated virions, etc.,
yielded promising results in SHIV 89.6-infected RM but had severely discordant results
in clinical trials; none of the vaccine candidates showed protection in humans70. SHIV
89.6 has undoubtedly served as a prototype for subsequent SHIV design.
In 2001, Cheng-Mayer and colleagues71 addressed the dual-tropism issue by
generating a novel SHIV encoding an exclusively CCR5-tropic clade B Env, SF162,
which was also derived from an AIDS patient. While this SHIV initially replicated suboptimally in RM similar to its predecessor, an analogous in vivo passage approach
yielded a more pathogenic viral swarm, SHIV SF162P3, which was both intravenously
and mucosally transmissible. The original Env encoded by this SHIV, however, was
found to be unusually sensitive to neutralization by antibodies72. The antigenic profile
and protein conformation of the SHIV 162P3 Env was recently described; it was found to
be unusually neutralization resistant to a number of bNAbs such as 4E10 that
neutralized all primary HIV-1 isolates tested73. Further, approximately 25-40% of RM
infected with SHIV SF162P3 exhibited spontaneous control of viremia by 8 weeks postinfection in the original report and in follow-up studies71,74; spontaneous control can be
defined as suppression of plasma viremia to below 102-3 c/ml.
In 2006, Ruprecht and colleagues generated the first clade C CCR5-tropic SHIV
1157ipd3N475 in an effort to address the lack of SHIVs encoding non-clade B Envs.
SHIV 1157ipd3N4 reproducibly infected RM after 3 passages. In addition, the group
added an additional NF-kB binding site to the SHIV genome, leading to enhanced in vivo
virulence due to increased LTR-driven viral gene expression. Like its predecessors,
SHIV 1157ipd3N4 is mucosally and intravenously transmissible; early viral kinetics are
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similar to HIV-1 infection. Despite all aforementioned modifications, set point viremia in
SHIV 1157idp3N4-infected RM is highly variable: 54% of RM (n=13) in the original study
spontaneously controlled viremia to below 10 3 c/ml by 28 WPI, 71% of which suppressed
viremia to below the limit of assay quantification (50 c/ml).
In 2010, a novel SHIV, AD8, was developed by Martin and colleagues76 with the
goal of generating a more neutralization-resistant CCR5-tropic virus. Serial passage
again led to the generation of a virulent viral swarm that resulted in CD4 T cell depletion
and progression to AIDS in most RM 76. This CCR5-tropic SHIV also exhibited variable
persistence, as approximately 20% of RM infected with this virus spontaneously
controlled viremia to <103 c/ml by 32 weeks post-infection76. An infectious molecular
clone (IMC) isolated from the SHIV AD8 swarm, EO77, consistently elicited autologous
neutralizing antibodies. Only 25-50% percent of RM infected with the original SHIV AD8
swarm, however, produced potent autologous neutralizing antibodies (>50%
neutralization compared to virus-only control) in multiple studies76,77.
In summary, these SHIVs and others have yielded important insights over the
several decades that they have been in use. SHIVs have been used to study the biology
of HIV-1 Env and its impact on virus-host interactions, transmission, and
pathogenesis67,71,78,77 and have been particularly important in evaluating Env-targeting
agents such as bNAbs56,57,79.
Collectively, previous iterations of SHIVs have several limitations in their ability to
reproduce key features of HIV-1 transmission and infection. The SHIVs described here
do not accurately recapitulate key properties of transmitted/founder (TF) and primary
HIV-1 isolates from early infection, such as CCR5 tropism 15,80,81,67, infection and
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depletion of relevant long-lived T cell subsets77,78, and induction of consistent autologous
antibody responses24,82,3,4. Further, most SHIVs do not fully reflect the original antigenic
conformation and neutralization sensitivity of native HIV-1 Env as a result of the serial
passage experiments that are necessary for productive infection of RM1,2,3,4. A small
number of SHIVs encoding primary or TF Envs have been shown to fortuitously confer
high peak and set point viremia in RM without adaptation; none of these SHIVs,
however, have been extensively characterized with regard to their antigenic
conformation or assessed for persistence in the presence of antiretrovirals83. In addition,
the mechanisms responsible for variable SHIV persistence and spontaneous control of
CCR5-tropic SHIVs in RM, as exhibited by SHIVs 162P3 and AD8, are as of yet
unknown.

A new generation of SHIVs
Recently, our group reported the development of a novel strategy to generate
designer SHIVs encoding native TF or primary Envs with Tier 2 neutralization sensitivity,
henceforth referred to as TF SHIVs84. Residue 375, which is located in the CD4 binding
site pocket of Env, was found to be under strong selection pressure across all primate
lentiviruses. In HIV isolates, the preferred residue at this position is serine, while in
SIVmac isolates, the preferred residue is bulky and hydrophobic (i.e. tryptophan,
tyrosine, histidine). Making a single amino acid substitution at Env position 375 mediated
increased affinity of HIV-1 Env for rhesus CD4. Env 375 substitution enables effective in
vitro and in vivo infection of RM while preserving the antigenic conformation and
neutralization sensitivity of the parental Env.
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TF SHIVs consistently confer productive infection, high peak viremia, and
desirable early viral kinetics when administered via mucosal or intravenous routes as
described in 84,85,86. Importantly, TF SHIVs are CCR5-tropic and have been shown to
reproducibly induce autologous antibody responses in infected RM, thereby
recapitulating key qualities of primary and TF HIV-1 isolates87. Further, the 20+ TF
SHIVs generated to date encode epidemiologically important Envs from clades that have
been underrepresented in previous iterations of SHIVs, including A, AE, C, and D,
among others84. Importantly, the ability to encode any Env of interest in TF SHIVs using
this novel approach presents a heretofore unrealized opportunity for the development of
a broadly effective HIV-1 vaccine. Characterizing Env-antibody co-evolution in RM that
develop bNAbs could serve as a roadmap for the development of an effective HIV
vaccine; studies describing the recapitulation of Env-antibody coevolution in a number of
RM infected with TF SHIVs that have developed bNAbs are ongoing87.

Goals of this thesis
Numerous important questions regarding the biology and suitability of SHIVs,
including TF SHIVs, as an NHP model for HIV-1 infection remain unanswered, including
those delineated here.
First, a subset of TF SHIV-infected RM exhibit variable viral persistence. The
incidence of spontaneous control is dependent on the TF SHIV. For instance, 7 of 30
non-CD8 depleted SHIV.CH505-infected RM in 3 independent studies controlled viremia
to around or below 102 c/ml by 12 weeks post-infection88,89,85. The incidence of
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spontaneous control in SHIV.CH505-infected RM is similar to other SHIVs in use,
including SHIVs 162P3 and AD871,76. The etiology underlying spontaneous viremic
control of SHIVs, including TF SHIVs, has never been identified, but could be
attributable to numerous factors. These factors could include a greater magnitude of
infection of shorter-lived or aberrant cell subsets, such as Tn76 and/or early development
of effective host innate and adaptive immune responses that result in differences in the
clearance and maintenance of reservoir cells in SHIV versus HIV-1 infection.
Second, there is a dearth of literature that addresses the suitability of SHIVS,
including TF SHIVs, for latency and cure research. Although multiple groups have and
continue to use SHIVs AD8 and 162P3 as reagents for preclinical studies of potential
HIV-1 cure strategies, including latency reversal agents (LRAs)56 and broadly
neutralizing antibodies57, no study has extensively characterized the reservoir biology
and pathogenesis of CCR5-tropic SHIVs before, during, and after cART administration in
the absence of an intervention. Studying SHIVs off and on cART in the absence of an
intervention would be beneficial for the design of more effective preclinical HIV-1 studies.
Third, the mechanisms underlying discordant results between preclinical and clinical
vaccine and other studies have been incompletely elucidated except in the case of SHIV
89.6. These results could be related to the unusual Env sequence and conformation
found in both SHIVs 162P3 and AD8 in comparison to TF Envs, the formation of a
potentially smaller reservoir in SHIV-infected RM versus PLWH due to the reasons
hypothesized earlier, or the significant genetic distance (up to 70%) between the fulllength chimeric SHIV genome and primary/TF HIV-1 isolates, among others.
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The goal of this dissertation is to evaluate 2 hypotheses broadly related to these
questions: 1) that the viral kinetics and reservoir biology of RM infected with TF SHIVs
both on and off cART recapitulate HIV-1 infection and 2) that serial SHIV passage in
tandem with mechanistic in vitro studies can be harnessed to engineer a SHIV.CH505
clone that confers enhanced viral kinetics.
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Abstract
A robust simian-human immunodeficiency virus (SHIV)-macaque model of
latency is critical to investigate eradicative and suppressive strategies that target HIV-1
Env. We previously reported a novel strategy for constructing SHIVs that bear primary
or transmitted/founder (TF) Envs with modifications at Env residue 375 that enables
efficient replication in Indian rhesus macaques (RM). Such TF SHIVs, however, have not
been examined for their suitability for HIV-1 latency and cure research. Here, we
evaluated two promising TF SHIVs, SHIV.D.191859 and SHIV.C.CH848, which encode
TF subtype D and C HIV-1 Envs, respectively, for their viral kinetics and persistence
during suppressive combination antiretroviral therapy (cART) and treatment interruption
in RM using single genome sequencing (SGS) as well as plasma vRNA and cellassociated DNA and RNA quantification.
These results suggest that the viral kinetics of these SHIVs in RMs during acute,
early and chronic infection, and upon cART initiation, maintenance and discontinuation,
mirror HIV-1 infection. TF SHIVs CH848 and 191859 demonstrate consistent early peak
and setpoint viremia, rapid declines in viremia to undetectable plasma titers following
cART initiation, infection of long-lived cellular subsets and establishment of viral latency,
and viral rebound with return to pretreatment setpoint viremia following treatment
interruption. The viral dynamics and reservoir biology of SHIV.D.191859, and to a lesser
extent SHIV.C.CH848, during chronic infection, cART administration, and upon
treatment interruption suggest that these TF SHIVs are promising reagents for a SHIV
model of HIV-1 latency and cure.
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Significance
SHIVs have been successfully used for over two decades to study virus-host
interactions, transmission, and pathogenesis in rhesus macaques. The majority of Env
trimers of most previously studied SHIVs, however, do not recapitulate key properties of
TF or primary HIV-1 isolates, such as CCR5 tropism, tier 2 neutralization resistance, and
native trimer conformation. Here, we test two recently generated TF SHIVs,
SHIV.191859 and SHIV.C.CH848, which were designed to address these issues as
components of a nonhuman primate model of HIV-1 latency. We conclude that the TF
SHIV-macaque model reflects several hallmarks of HIV and SIV infection and latency.
Results suggest that this model has broad applications for evaluating eradicative and
suppressive strategies against the HIV reservoir, including Env-specific interventions,
therapeutic vaccines, and engineered T cells.
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Introduction
Chimeric simian-human immunodeficiency viruses (SHIVs), which encode an
HIV-1 envelope glycoprotein (Env) within the background of a macaque-adapted simian
immunodeficiency virus (SIVmac) backbone, have wide-ranging applications for
evaluating HIV pathogenesis, vaccine and cure strategies 67. SHIVs have been
successfully used for over two decades to study virus-host interactions, transmission,
and pathogenesis in non-human primates such as rhesus macaques(RM)67,71,76. SHIVs
have particular importance as reagents in studies testing strategies that engage Env,
such as broadly neutralizing antibodies (bNAbs) and antibody-based vaccines, and in
dissecting the immunology behind antibody elicitation 55–57,79.
Previous iterations of SHIVs, however, have several limitations. Many SHIVs do
not accurately recapitulate key properties of transmitted/founder (TF) or primary HIV-1
isolates from early infection, such as CCR5 tropism15,32,67,81, infection and depletion of
relevant long-lived T cell subsets77,78, and induction of consistent autologous tier 2
antibody responses76,77,24,82. Further, most SHIVs do not fully reflect the original
conformation and neutralization sensitivity of native HIV-1 Env as a result of adaptations
acquired through extensive in vitro and in vivo passage required to enable efficient
infection of RM cells67,71,76. A small number of SHIVs encoding primary Envs have been
shown to fortuitously replicate in RM without adaptation; none of these SHIVs, however,
have been characterized for persistence before, during and after antiretroviral therapy 83.
Recently, we reported the development of a novel strategy to generate designer
SHIVs encoding native TF or primary Envs with Tier 2 neutralization sensitivity, referred
to here as “TF SHIVs”84. In this method, a single amino acid substitution at Env position
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375 mediates increased affinity of HIV-1 Env for rhesus CD4, enabling efficient in vitro
replication in rhesus cells and in vivo infection of RMs while preserving the antigenic
properties of the parental Env. TF SHIVs consistently confer productive infection
through multiple inoculation routes, high peak viremia, and desirable early viral kinetics.
Importantly, TF SHIVs are CCR5-tropic and have been shown to reproducibly induce
autologous antibody responses in infected RM, thereby recapitulating key qualities of
primary and TF HIV-1 isolates84,87. Prior to this year, TF SHIVs had not yet been
evaluated for their suitability for studies of HIV cure and latency.
Here, we evaluate two genetically and antigenically diverse TF SHIVs,
SHIV.D.191859 and SHIV.C.CH848, which encode TF subtype D and C HIV-1 Envs,
respectively, for their viral kinetics and persistence during suppressive combination
antiretroviral therapy (cART) and treatment interruption in RM. Our results indicate that
the kinetics of SHIV.D.191859 and SHIV.C.CH848 infection and replication in RMs
during acute, early and chronic infection and upon cART initiation and discontinuation
mirror HIV-1 infection. The findings presented thus provide an experimental framework
with which to design future preclinical studies of HIV-1 latency, cure and
immunopathogenesis.

Materials and Methods
Nonhuman Primates
Indian-origin RMs were maintained at Tulane National Primate Research Center
(TNPRC) according to the standards of the Association for Assessment and
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Accreditation of Laboratory Animal Care. All experiments were approved by the Tulane
Animal Care and Use Committee. All animals were tested and found to be negative for
described SIV controller alleles Mamu-A*01, B*08, and B*17, except for RM DE33,
which was A*01 positive. Whole blood from animals was processed using centrifugation
as described84. PBMCs were isolated using Ficoll-Paque (GE Healthcare) gradient
centrifugation. Plasma was clarified by centrifugation for 15 min at 3000 rpm, frozen,
thawed, and then subject to viral RNA extraction as described below. SHIV VL levels in
plasma were determined by the Pathogen Detection and Quantification Core at the
TNPRC using quantitative real-time reverse-transcription PCR of SIV RNA as previously
described90; the assay limit of quantification (LOQ) was 83 c/ml.

Construction and Viral Stock Characterization of SHIV.D.191859 and
SHIV.C.CH848
SHIV.D.191859 and SHIV.C.CH848 constructs were generated and viral stocks
were made as described84. Briefly, for the 293T-derived SHIV.C.CH848 stock, 6 ug of
plasmid DNA and 18 ul of FuGENE 6 (Promega) transfection reagent were added to a
pre-seeded Petri dish containing 3.6X106 293T cells in 10 mL of complete media (DMEM
with Glutamax (Gibco) supplemented with 10% FBS (Hyclone) and 100 U/ml
penicillin/streptomycin (Gibco)). After 48 hours, the supernatant was transferred to a 15
mL conical and spun at 3000 rpm for 15 minutes. The clarified viral supernatant was
aliquoted and frozen at -80C. The rhesus CD4-derived SHIV.D.191859 stock was
generated as described in

84
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The virion content of viral stocks was quantified in triplicate using the p27Ag 96well ELISA kit from ZeptoMetrix; the manufacturer’s instructions were followed without
deviation. The infectivity of viral stocks was determined via titration on TZM-bl cells in
quadruplicate. Briefly, TZM-bl cells were obtained from the NIH AIDS Reagent Program.
10,000 cells/well were seeded in a 96-well tissue culture plate in 100 ul/well complete
media (DMEM with Glutamax (Gibco) supplemented with 10% FBS (Hyclone) and 100
U/ml penicillin/streptomycin (Gibco)). The following day, virus stocks were serially diluted
5-fold in complete media supplemented with 40 ug/ml of DEAE-Dextran (Thermofisher)
in titer tubes, with an initial virus stock dilution of 1:5. Virus stock dilutions were
transferred in quadruplicate to TZM-bl cells. After 48 hours, cells were stained with betagalactosidase and infectious titer was calculated as described in

91.

Virion content for the rhesus PBMC-derived SHIV.D.191859. and 293T-derived
SHIV.C.CH848 stocks were 211 and 2342 ng p27Ag/ml, respectively. The
SHIV.D.191859 and SHIV.C.CH848 infectivity-to-particle ratios as determined on TZM-bl
cells were 1.510-2 and 5.510-4 IU/particle, respectively, which is similar to other TF
SHIV stocks84.

SHIV.D.191859 and SHIV.C.CH848 Inoculation
Six RM were intravaginally challenged with one mL of undiluted
SHIV.D.191859.dCT containing 3.19107 infectious units (IU) as determined on TZM-bl
cells. Two RM (FE43 and EJ94) became productively infected following the first
challenge. 4 RM that remained uninfected were intravaginally challenged with one mL of
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stock dilutions of 1:10 at week 12, 1:4 at week 16, and 1:2 at week 23. After four
challenges, two RM (FR55 and GA67) remained uninfected; these RM were
intravenously inoculated with 1.00106 IU of SHIV.D.191859 at week 48, which resulted
in productive infection of both animals. In a separate study, four RM were intravenously
challenged with one mL of undiluted SHIV.C.CH848.dCT stock containing 1.29107
infectious units (IU) as determined on TZM-bl cells; all RM became productively infected.

Viral Sequencing
Single-genome gp160 env sequences were generated as described84. Briefly,
20,000 viral RNA copies were extracted from plasma by means of the Qiagen BioRobot
EZ1 Workstation with the EZ1 Virus Mini Kit v2.0 (Qiagen). Eluted vRNA was
subsequently used as a template for cDNA synthesis and reverse-transcribed using the
reverse primer SHIV.Env.R1 (5′- TACCCCTACCAAGTCATCA-3′) and SuperScript III
reverse transcriptase (Invitrogen Life Technologies). cDNA was serially diluted in a 96well plate (Applied Biosystems) to identify the dilution at which less than 30% of wells
contained PCR amplicons of the correct size. The SHIV gp160 env genome was
amplified via nested PCR with primers as follows: first round forward primer
SHIV.Env.F1 (5′- CGAATGGCTAAACAGAACA-3′), second round forward primer
SHIV.Env.F2 (CTACCAAGGGAGCTGATTTTC), first round reverse primer SHIV.Env.R1
(5′- TACCCCTACCAAGTCATCA-3′), and second round reverse primer SHIV.Env.R2 5’TATTTTGTTTTCTGTATGCT-3’). PCR conditions were used as follows for the first
round of nested PCR: 94°C, 2 min; 37x [94°C, 20 sec; 55°C, 30 sec; 68°C, 3 min 30
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sec]; 68°C, 10 min. For the second round of nested PCR, the PCR conditions were as
follows: 94°C, 2 min; 42x [94°C, 20 sec; 54°C, 30 sec; 68°C, 3 min 30 sec]; 68°C, 10
min. Amplicons were sequenced via the MiSeq platform (Illumina). Raw reads were
aligned to the SHIV.D.191859 or SHIV.C.CH848 TF reference using Geneious R9.
Sequences that contained mixed bases at a frequency of greater than 25% per
nucleotide position were excluded from further analyses.

TF Estimation
To approximate the minimum number of virus-infected cells that contributed to
recrudescent viremia, we generated a conservative estimate of the amount of genetic
diversity that could accrue in the time elapsed post-ATI. We used the median error rate
for HIV-2 reverse-transcriptase (RT) reported by Rawson et al.92 (3.110-4
mutations/nucleotide base), as SIVmac is more closely related to HIV-2 than HIV-17; of
note, error rates for both HIV-1 and HIV-2 RT are reported to be very similar93. We
assumed a virus-infected cell generation time of 1.5 days based on previous
studies21,22,94. We multiplied HIV-2 RT error rate (3.110-4 mutations/nucleotide base) by
average TF SHIV gp160 env amplicon length (3693 bp) and divided this number by the
virus-infected cell generation time (1.5 days) to estimate the amount of genetic diversity
that could accrue in a day. We then multiplied the resulting number by the number of
days elapsed post-ATI to estimate the maximum amount of genetic diversity that could
accrue in each virus population during this period, subtracting four days from the number
of days elapsed post-ATI to account for a conservative terminal drug washout period
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based on previous pharmacokinetic elimination studies in HIV-1-infected humans95. The
equation used for estimating the maximum accrued diversity post-ATI for each RM is
thus summarized as: (3.110-43,693(days elapsed post-ATI-4))/1.5. Data regarding
the complete pharmacokinetic elimination and drug metabolism of tenofovir,
emtricitabine, and dolutegravir in HIV-1 infected humans and SIV and SHIV-infected
rhesus macaques are limited, to date 96–98. This estimate was used to determine the
maximum divergence one reactivating lineage unaffected by recombination could accrue
during ATI, which allowed us to enumerate the minimum number of independent
reactivation events during systemic viral rebound at the time of sampling based on
divergence from neighboring lineages.

Phylogenetic Analyses
Maximum-likelihood phylogenetic trees were generated using the HKY85
substitution model and a transition/transversion ratio of four in PhyML Version 3.0 and
visualized in FigTree99. Maximum pairwise diversity measurements of pre and postcART virus populations were calculated using DIVEIN 100.

Flow Cytometric Sorting of PBMC and LNMC
Antibodies used for CD4 T cell subset sorting. The following antibodies were
obtained from Biolegend: CD8 AF647 (clone RPA-T8), CD14 BV650 (clone M5E2),
CD16 BV650 (clone 3G8) and CD20 BV650 (clone 2H7). The following antibodies were
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obtained from BD Biosciences: CD3 APC-Cy7 (clone SP34-2), CD95 PE-Cy5 (clone
DX2), HLA-DR BV421 (clone G46-6). CD28 ECD (clone CD28.2) was obtained from
Beckman Coulter. CD4 PE-Cy5.5 (clone S3.5) was obtained from Life Technologies.
The Live/Dead Fixable Aqua Dead Cell Stain Kit (Invitrogen) was used for viability
exclusion.
Sorting for CD4+ T cell subsets. Cryopreserved PBMC or LNMC were thawed,
counted, examined for viability and rested for two hours at 37°C and 5% CO 2 in
complete medium (RPMI supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml
penicillin, and 100 mg/ml streptomycin). All incubation ns were performed in the dark at
room temperature. Cells were stained for viability exclusion for 10 minutes. Undiluted
antibody cocktail mix was added and incubated for 20 minutes. Following surface
staining, cells were washed and resuspended in phenol-free RPMI, and kept in the dark
at 4°C. Cells were sorted on a FACSAria II (BD Biosciences). Sorted cells were washed
with PBS and pelleted at -80°C until processing. Tn were identified as CD28+ CD95CD4 T cells. Tcm were identified as CD28+ CD95+ CD4 T cells. Resting memory CD4 T
cells were identified as CD95+ HLA-DR- CD4 T cells.

Quantification of Cell-Associated SHIV DNA and RNA in PBMC and Tissues
Cellular DNA was purified using the AllPrep DNA/RNA kit (Qiagen) as specified by
the manufacturer and normalized to cell equivalents by qPCR using a non-human
primate-specific TaqMan hRNase P primer-probe assay (Life Technologies). Total
cellular SHIV DNA was quantified in a qPCR reaction using primers and probe specific
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to the SIVmac239 LTR region (Forward Primer: 5’TACCCAGAAGAGTTTGGAAGCAAGTCA-3’, Reverse Primer: 5’TTGTCAGCCATGTTAAGAAGGCCTCTTG-3’ and Probe A: 5’-(FAM)
CTGTCAGAGGAAGAGGTTAGAAGAAGGCTAAC (BHQ1)-3’ (Integrated DNA
Technologies). PCR reaction mixtures each contained 10 µl of 2X Taqman Universal
Master Mix II (Life Technologies), 6 pmol of each primer, 6 pmol of probe, and 5μl of
DNA (total volume of PCR reaction = 20 ul). PCR cycle conditions were as follows:
50°C, 2 min; 95°C, 10 min; 50x [95°C, 15s; 60°C,1 min); PCR was performed on an ABI
7500 FAST machine (Life Technologies). External quantitation standards were prepared
using DNA isolated from the SIV1C cell line, which has a single copy of SIV DNA per
cell; this was followed by copy number determination using RainDance Digital Droplet
PCR (RainDrop). Specimens were assayed in replicate reaction wells. Copy number
was determined by extrapolation against an 8-point standard curve (1–100,000 copies),
which was performed in triplicate. Due to low viable PBMC and LNMC recovery for some
SHIV.C subset samples, the ca-DNA LOQ varied, and ranged between 20 to 1500
copies per sample (Figure 2.6D-F). Similarly, ca-RNA measurements for two SHIV.Dinfected RM (RM FE43 and GA67) were not detectable at month six due to low cell
yields and therefore were excluded from Figure 2.2B.

qPCR quantification of cellular SIV RNA. Cellular RNA was purified using the
AllPrep DNA/RNA kit (Qiagen) as specified by the manufacturer and was normalized to
cell equivalents by qPCR using the non-human primate-specific TaqMan RPLPO primerprobe assay (Life Technologies). Total cellular SHIV RNA was quantified using a two30

step RT-PCR assay. First, 250 ng of RNA were reverse transcribed to produce cDNA
using the VILO IV reverse transcriptase enzyme and random hexamer primers
(Invitrogen) according the manufacturer’s instructions. cDNA was quantified in a qPCR
reaction using primers and a probe specific to the SIVmac239 LTR region (Forward
Primer: 5’-TACCCAGAAGAGTTTGGAAGCAAGTCA-3’, Reverse Primer: 5’TTGTCAGCCATGTTAAGAAGGCCTCTTG-3’ and Probe A: 5’-(FAM)
CTGTCAGAGGAAGAGGTTAGAAGAAGGCTAAC (BHQ1)-3’ (Integrated DNA
Technologies)). Each reaction contained 10 µl of 2X Taqman Universal Master Mix II
(Life Technologies), 6 pmol of each primer, 6 pmol of probe, and 5μl of cDNA, with a
total reaction volume of 20 ul. PCR cycle conditions were as follows: 50°C, 2 min; 95°C,
10 min; 50x [95°C, 15s; 60°C,1 min); PCR was performed on an ABI 7500 FAST
machine (Life Technologies). qPCR runs were carried out using an ABI 7500 FAST
Machine (Life Technologies). External quantitation standards were prepared using
SIVmac239 RNA followed by copy number determination using the RainDance Digital
Droplet PCR (RainDrop, MA). Specimens were assayed in replicate reaction wells.
Copy number was determined by extrapolation against a 6-point standard curve (3–
300,000 copies), which was performed in triplicate.

Logo plot generation.
For each RM, sequence alignments from pre-cART and first detectable rebound
were compared. Any amino acid position with greater than 20% change in identity
between timepoints were included in analyses. Logo plots were generated on
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AnalyzeAlign
(https://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze_align.html).

Statistical Analyses
Statistical analyses were performed using Prism 7.0 software (Graphpad). Given
small sample sizes (n=4 to 6), nonparametric tests were used for all statistical
comparisons. The Wilcoxon signed-rank test was used to test for changes in withinanimal measures of viral diversity and latency pre- and post-cART administration.
Spearman’s rank-order correlation test was used to assess the association between
measures of latency. The Mann-Whitney test was used to assess the relationship of caDNA and ca-RNA levels in PBMC in RM infected with SHIV.D versus SHIV.C.

Results
SHIV.D.191859 and SHIV.C.CH848 early viral kinetics.
Two TF SHIVs with desirable viral kinetics, SHIV.D.191859 and SHIV.C.CH848,
hereafter referred to as SHIV.D and SHIV.C, were evaluated for their suitability for
latency and cure studies. SHIV.D encodes a subtype D TF Env identified from an
acutely infected Ugandan woman in 2008 32. The HIV-1 TF virus was shown to be
CCR5-tropic, with a tier 2 neutralization profile and the capacity to replicate in both CD4
T cells and macrophages32. SHIV.C encodes a clade C Env identified in an acutelyinfected Malawian man in 2008101. Subsequently, infection with this virus was shown to
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elicit N332-dependent V3-targeting bNabs after 3.5 years of infection. A strategy for
eliciting CH848-like bNabs in humans via vaccination has been described 101; further,
similar bNabs have been elicited in SHIV.C.CH848-infected RM87. Prior to the current
study, SHIV.D and SHIV.C had each been used to infect 6 non-CD8 depleted RM, with
mean peak VLs of 106-7 c/ml for both SHIVs; 10 of 12 SHIV.C and SHIV.D-infected RM
maintained viremia above 103 c/ml through 24 weeks post-infection (WPI)84

SHIV.D.191859 persists on suppressive cART.
To evaluate SHIV.D infection after early time points and its response to cART, 6
RM were intravaginally challenged with increasing doses of SHIV.D until infection was
confirmed by repeated positive plasma VL (VL) measurements. 2 RM demonstrated
infection after the first challenge and 2 additional RM became productively infected after
the third challenge (Figure 2.1). 2 RM remained uninfected after 4 intravaginal
challenges and were subsequently inoculated intravenously, demonstrating productive
infection at day 7. Peak viremia ranged from 9.7105 to 4.2107 c/ml and levels did not
appear substantially different between animals infected by mucosal versus intravenous
routes (mean peak VL = 1.4107 c/ml versus 2.1106 c/ml, respectively).
RM were followed longitudinally through early infection and establishment of a
relatively stable viral set point (Figure 2.1). In all 6 RM, viremia above 103 c/ml was
maintained for at least 24 weeks, with set point VLs ranging from 103 to 106 c/ml. After
42 WPI, RM FT42 spontaneously controlled plasma viremia to below the assay LOQ (83
c/ml) and was excluded from further analysis. RM DE33 was euthanized at 66 WPI after
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viremia rose to greater than 10 6 c/ml coincident with signs and symptoms of severe
illness; this RM was positive for the Mamu A*01 allele, which is significantly associated
with frequency of spontaneous viremic control of SIV infection 102. In this small cohort, the
mean set point VL did not appear to be substantially different between animals that were
productively infected via mucosal or intravenous inoculation (mean set point VL =
3.0105 versus 1.6105 c/ml, respectively).
We evaluated persistence of SHIV.D on suppressive cART in the 4 remaining
viremic RM using daily injectable combination antiretroviral therapy (cART) consisting of
dolutegravir, emtricitabine, and tenofovir. Viral suppression below 83 c/ml was achieved
between 7 to 21 days of cART initiation and durably maintained in all RM. One
incidence of detectable viremia to 804 c/ml occurred in EJ94 16 weeks post-cART
initiation. cART was discontinued after 24 weeks. Rebound plasma viremia was
detected between 7 and 19 days post-treatment interruption (Figure 2.1). Plasma virus
rebounded to at or near the pre-cART set point VL in all RM (103 to 107 c/ml by four
weeks post-rebound).
We next quantified the levels of cell-associated viral DNA (ca-DNA) and RNA
(ca-RNA) in PBMCs sampled during chronic infection in SHIV.D-infected RM prior to
cART initiation (Figure 2.2). The mean ca-DNA measurement in PBMC was 9.9102
copies/106 cells and remained detectable after four months of cART suppression in all
four RM, with a mean 1.9-fold decrease. The mean ca-RNA level was 5.4103
copies/106 cells and similarly decreased 2.0-fold, on average, after four months of cART.
Measurements of ca-DNA and RNA were similar at four and six months of cART.
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SHIV.D.191859 diversity pre- and post-cART
We next characterized the diversity of SHIV populations by longitudinal single
genome sequencing (SGS) of gp160 env sequences; 284 total sequences (median 31
per animal timepoint) were generated. To characterize peri-maximal SHIV diversity,
plasma virus was sequenced immediately prior to cART-initiation, when the four RM had
been productively infected for between 33 to 81 weeks (Figure 2.3), revealing a
maximum within-animal env pairwise diversity between 1.0-2.5%.
To characterize the rebound virus populations reactivating from latency upon
treatment interruption, sequences were generated from the first time point where plasma
VL was greater than 500 c/ml. Maximum likelihood phylogenetic trees comparing the TF
SHIV.D env sequence and pre-cART and rebound plasma virus populations are shown
in Figure 2.3. Maximum within-animal pairwise diversity values at the time of first
detectable rebound were not significantly different from pre-cART values, ranging from
0.3-1.9% (p=0.25, n=4, Wilcoxon signed-rank test).
To enumerate the minimum number of virus-infected cells that contributed to
recrudescent viremia, we used a conservative estimate of the amount of genetic
diversity that could accrue in the elapsed time post-treatment interruption. For these 4
RMs, the maximum diversity estimate discriminating between variants ranged between
three and 19 nts per env sequence, based on differences in time to rebound (see
methods). For example, RM EJ94 had the fastest time to rebound of the four RM (seven
days). Given an estimated mutation rate of 0.76 nt per amplified viral genome per day,
35

time to rebound, and an approximate terminal drug washout period of four days, we infer
that the maximum divergence one reactivating lineage could accrue within env between
reactivation and our sampling is two nucleotide substitutions. Thus, virus lineages that
differ in env by more than two nucleotides are likely representative of distinct reactivating
cells. FE43, in contrast, had the slowest time to rebound (19 days). For this RM, our
model likely overestimates the maximum divergence one reactivating lineage could
accrue, as virus is unlikely to be consistently replicating for 15 days prior to systemic
detection. Using this diversity cut-off, rebound virus populations in the four RM grouped
into between seven (FE43), ten (FR55), and 13 (EJ94) low-diversity lineages at first
detectable viral rebound in three of four RM. In GA67, sequences fell into either one or
two closely related lineages at day 12 post-ATI. One week later, at day 19 post-ATI, six
genetically distinct low-diversity lineages were sampled in RM GA67. Thus, in all four
RM, rebound viremia was founded by multiple virus-infected cell reactivations.

SHIV.D.191859 and CD4 T cell quantification in tissues
To assess the extent of systemic virus dissemination and CD4 T cell depletion in
SHIV.D-infected RM, we quantified CD4 T cell percentage, total SHIV DNA, and total
SHIV RNA in lymphoid and other tissues following euthanasia due to either clinical
indication or study end point. RM DE33 and EJ94 were euthanized due to clinical
disease progression at 18 and 39 months post-infection MPI), respectively. RM FR55
and GA67 were re-suppressed on cART at 39 and 34 MPI, respectively. RM FR55 was
electively euthanized 6 months later at 45 MPI, while RM GA67 was euthanized due to
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clinical indication at 35 MPI after one month of cART re-suppression. RMs FE43 and
FT42 were euthanized per study protocol; FE43 while viremic at 40 MPI and RM FT42
while virally suppressed off cART at 36 MPI, after 25 months of spontaneous virus
control. In the two RM with clinical progression coincident with high viremia, CD4 T cells
were depleted and levels of HIV DNA and RNA high throughout the body. In RM EJ94,
analysis of PBMC and all lymphoid tissues, including gut-associated lymphoid tissues
(GALT), spleen, and lymph nodes, revealed severe CD4 T cell depletion at necropsy
(0.9-2.5% of total T cells, Figure 2.4A). In RM DE33, a similarly severe degree of CD4 T
cell depletion was observed in GALT, including the colon and ileum (4.7 and 6.0% of
total T cells, respectively) as well as in bone marrow (7.0%, Figure 2.4A). In RM with
less SHIV-associated disease progression, CD4 T cell depletion was more moderate
and levels of SHIV DNA and RNA lower throughout. Despite spontaneously
suppressing plasma viremia, RM FT42 had detectable ca-DNA and RNA in multiple
tissues at necropsy. Across the six RM, SHIV DNA and RNA quantification showed
systemic virus dissemination in every tissue sampled from all SHIV.D-infected RM,
which included GALT, lymph nodes, tonsil, and spleen (Figure 2.4B-C). The mean total
SHIV DNA and RNA measurements across all sampled tissues in all RM were 3.4104
and 2.9107 copies/106 cells, respectively (Figure 2.4B-C).

SHIV.C.CH848 infection pre- and post-cART.
We next examined SHIV.C infection for persistence on cART. Four RM were
intravenously challenged with a high-dose SHIV.C inoculum. All animals became
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productively infected with peak VL ranging from 105 to 107 c/ml (Figure 2.5). In all four
RM, viremia was maintained through 16 WPI, with set point VLs ranging from 10 3 to 105
c/ml. After 16 weeks of infection, cART was initiated. Viral suppression below 83 c/ml
was achieved in all RM within seven days post-cART initiation and was durably
maintained for 24 weeks. cART was discontinued at 24 weeks post-infection, with
recrudescent plasma viremia detected within five to 22 days of treatment interruption. As
with SHIV.D-infected animals, RM with higher pre-cART viremia rebounded earlier
(Figure 2.5). Post-rebound, the four RM re-established a quasi-set point VL at ~1-1.5
log10 c/ml below pre-cART levels. For KK54, this led to consistent viremia (~104 c/ml).
For the remaining three RM, lower levels of systemic virus replication were detected
post-ATI, with intermittent declines of viremia below 83 c/ml. In KH83, the animal with
the lowest viremia pre-cART, virus initially rebounded shortly post-ATI, but then fell to
below the limit of assay detection one week later and remained undetectable for 21
weeks until rising to 103 c/ml through 24 weeks post-rebound. The two RM with
intermediate VLs pre-cART had post-rebound viremia that ranged from less than 10 2 to
greater than 103 c/ml through 24 weeks.
We then quantified the levels of ca-DNA and ca-RNA in SHIV.C-infected PBMC
at peak infection (3 WPI), at chronic infection (12 WPI), and after 12 weeks of cART to
characterize the dynamics of PBMC infection throughout the course of the study (Figure
2.6). At peak infection, the mean ca-DNA and ca-RNA measurements were 6.0103 and
6.9105 copies/106 cells, respectively (Figure 2.6A-B). During chronic infection, ca-DNA
and ca-RNA levels decreased to 7.8102 and 3.9103 copies/106 cells, respectively
(Figure 2.6A-B). The levels of ca-DNA and ca-RNA in chronic SHIV.C infection were
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similar to chronic SHIV.D infection (p=1 and 0.89, respectively, n=4, Mann-Whitney test).
Notably, after 3 months of cART administration, ca-DNA and ca-RNA decreased less
than 1 log10 to 3.5102 and 7.3102 copies/106 cells, respectively (Figure 2.6A-B).
To provide greater understanding of latency measures in long-lived cell
populations, we sampled PBMC and lymph node mononuclear cells (LMNC) and
quantified ca-DNA in several T cell subsets over time: central memory CD4 T cells (T cm),
naïve CD4 T cells (Tn), and total resting memory CD4 T cells (Figure 2.6D-F). In all
assayed subsets, the magnitude of infection was highest at peak infection (3 WPI),
decreased by 4.6-fold across all subsets during chronic infection (15 WPI), and further
decreased by 3.2-fold after 22 weeks of cART (Figure 2.6D-F). Tcm ca-DNA was highest
in both PBMC and LNMC at peak infection (mean = 4.7104 copies/106 cells), decreased
by 6.1-fold after 15 WPI (mean = 7.7103 copies/106 cells) and further decreased by 3.9fold after 22 weeks of cART (mean = 2.7103 copies/106 cells, Figure 2.6D). Notably,
ca-DNA in this long-lived subset remained detectable in all RM despite more than 20
weeks of cART suppression. In Tn and total resting memory CD4 T cells, decay kinetics
upon cART initiation were comparable to Tcm (Figure 2.6E-F). Total resting memory T
cells and Tcm were infected at a similar magnitude at peak and chronic time points, while
Tn were infected at a decreased frequency at peak and chronic infection (mean = 6.8
and 4.8103 copies/106 cells, respectively, Figure 2.6D-F)

SHIV.C.CH848 diversity before and after suppressive cART.
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We next characterized the diversity of SHIV populations by SGS of gp160 env
sequences. A total of 341 sequences (median 27 per animal timepoint) were generated.
To characterize peri-maximal env diversity, plasma virus was sequenced two weeks
prior to cART initiation at 14 WPI (Fig 7). SGS sequences revealed a maximum withinanimal pairwise diversity of 0.7-1.2%. Rebound plasma was sampled twice weekly posttreatment interruption and sequences were generated from the time of first detectable
rebound. Maximum likelihood phylogenetic trees comparing pre-cART and rebound
plasma virus env sequences with the TF SHIV.C env sequence are shown in Figure 2.7.
Maximum within-animal pairwise diversity measurements at the time of first detectable
rebound were not significantly different from pre-cART values (range = 0.1-0.8%,
p=0.13, n=4, Wilcoxon signed-rank test). At first detectable rebound, we sampled
multiple genetically distinct virus populations in three of four RM. Rebound virus
sequences clustered into between three and 11 discrete low-diversity lineages. The
exception, RM KH83, exhibited a monoclonal virus population at rebound and had
correspondingly low diversity measures (0.1%). While the rebounding virus population
was polyclonal in three of four RM, fewer rebound lineages were identified in SHIV.C
versus SHIV.D-infected RM.
To determine whether virus populations persisted through periods of control or
were cleared and replaced with novel viruses, plasma virus was sequenced
longitudinally (Figure 2.7). In both KM65 and KM11, we found that the lineages present
at first detectable rebound persisted over time despite intermittent periods of
undetectable (<83 c/ml) viremia. In KM65, for example, at first detectable rebound (15
days post-ATI), three distinct low-diversity lineages were present. Sequences from 19
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days post-ATI were identical or closely related (one to three nt different) to those at 15
days post-ATI, with two additional low-diversity lineages sampled. Sequences from day
56 post-ATI, which followed a short period of spontaneous control, formed 1 distinct lowdiversity lineage that was closely related (one to eight nt different) to lineages sampled
at 15 and 19 days post-ATI. Similar results were identified in RM KM11 at days 42 and
49 post-ATI following a period of viral suppression (Figure 2.7). In RM KK54, which
maintained viremia above the assay LOQ throughout the post-rebound period, four of 11
virus lineages sampled at first detectable rebound (12 days post-ATI) persisted at 22
and 29 days post-ATI. An additional six and four distinct lineages were sampled at 22
and 29 days post-ATI, respectively.

Rebound virus population diversity.
To assess how virus populations changed in response to cART treatment, we
compared pre-ART and rebound virus sequences. Shown in Figure 2.8 are LOGO plots
depicting all amino acid positions with greater than 20% change in identity between precART and rebound plasma virus populations. The vast majority of positions, not shown
in the LOGO plots, were relatively fixed from pre-cART to rebound. In positions with
diversity in virus replicating at cART initiation, overall diversity modestly decreased. This
was most notable in RM with mono- or oligoclonal rebound, e.g., GA67, KH83, and
KM65. RM that went on to experience post-rebound control generally had fewer
rebound variants and thus less virus diversity at rebound. Beyond lower relative
diversity, we found no specific sequence signature of post-rebound virus control. In the
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majority of studied RM that experienced polyclonal rebound, pre-cART virus diversity
was better retained at rebound, albeit with shifts in relative frequencies at specific
positions. At rare positions in RM with greater numbers of rebounding viruses, virus
diversity increased at select positions, as either minor or ancestral variants rebounded to
replicate systemically.
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Figure 2.1. SHIV.D.191859 viremia over time. A. Plasma viremia (c/ml, y axis) is
depicted longitudinally with week post-infection indicated on the x axis. Mucosal
inoculation is indicated by a black arrow; intravenous inoculation is indicated by a red
arrow. Euthanasia is indicated by a black cross. Time of cART administration (24 weeks)
is shown as a shaded grey box. B. Time to virus suppression after cART initiation and
time to detectable plasma viremia after ATI are shown for each RM.
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Figure 2.2. SHIV.D.191859 quantification over time. Cell-associated DNA levels in
PBMC (A), cell-associated RNA levels in PBMC (B), and matched plasma VL
measurements (C) are shown for all SHIV-infected RM. Pre-cART samples were
obtained during chronic infection (>33 WPI); a second and third set of samples were
obtained after 16 (month 4) and 23 (month 6) weeks of cART suppression, respectively.
Limit of quantification (LOQ) is denoted by the dashed line.

44

A. EJ94

SHIV.D.191859 TF
Pre-cART
Rebound week 1
Rebound week 2

D. GA67

B. FE43

10 nt

C. FR55

10 nt

10 nt

45

10 nt

Figure 2.3. Phylogenetic trees of longitudinal SHIV.D.191859-infected RM env
sequences. The TF SHIV.D sequence is shown in pink, pre-cART sequences are
shown in black, sequences from the first and second weeks of detectable viremia after
ATI are shown in blue and orange, respectively. Genetic distance is indicated by scale
bar, indicating 10 nucleotides or ~0.3% difference. Sequences are shown from RM EJ94
(A), RM FE43 (B), RM FR55 (C), and RM GA67 (D).
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Figure 2.4. SHIV.D.191859 and CD4 T cell quantification in tissues. CD4 T cell
percentages (A), total SHIV DNA (B), and total SHIV RNA (C) are shown for tissues from
all SHIV.D-infected RM at necropsy. Euthanasia was performed at different timepoints,
for clinical indications or at study completion. RM DE33 and EJ94 were euthanized while
viremic for clinical indication at 18 and 39 study months, respectively. RM GA67 and
FR65 were euthanized while on cART; FR55 after 6 months of cART by study protocol
and GA67 after 1 month of cART due to clinical deterioration. FE43 was euthanized
while viremic at study month 40. RM FT42 spontaneously controlled viremia to below the
assay LOQ and was euthanized with suppressed virus off cART. MLN = mesenteric
lymph node, ALN = axillary lymph node, BM = bone marrow, PLN = pharyngeal lymph
node, and BAL = bronchoalveolar lavage. Asterisks indicate tissue not collected or
analyzed.
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Figure 2.7. Phylogenetic trees of longitudinal SHIV.C.CH848-infected RM env
sequences. TF reference sequence is shown in pink, pre-cART sequences are shown
in black, sequences from the first, second, and third longitudinal rebound time points
following ATI are shown in blue, orange, and green, respectively. Genetic distance is
indicated by scale bar, indicating 10 nucleotides, or ~0.3% difference. All RM were
viremic for 16 weeks prior to cART initiation. A. Rebound sequences from RM KH83 at
29 days post-ATI. B. Rebound sequences from RM KM11 at days 19, 42, and 49 postATI. C. Rebound sequences from KM65 at days 15, 19, and 56 post-ATI. D. Rebound
sequences from RM KK54 at days 12, 22, and 29 post-ATI.
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Figure 2.8. Rebound virus diversity. Logo plots depicting amino acid positions with
greater than 20% change in identity between pre-cART and rebound timepoints are
shown for each RM. Variable positions from pre-cART and first detectable rebound
(R1) are shown for each RM. The second timepoint of rebound (R2) is shown for RM
GA67, in which additional rebound lineages arise a week after the R1 timepoint. The
third rebound timepoint is shown for KK54, which experienced persistent viremia postATI, and KM65, which had periods of virus control post-ATI.
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Discussion
NHP models of HIV/AIDS have been fundamental to elucidating key features of
HIV transmission, pathogenesis, persistence and response to therapy. As the field
continues to explore cure strategies, development of an NHP model that mirrors key
features of HIV persistence is essential. A model with viruses encoding primary HIV-1
Envs facilitates more direct testing of HIV-1 Env-targeting strategies and is a priority.
Here, we tested the capacity of two TF SHIVs to demonstrate key features of HIV-1
replication and persistence on cART. We found that both SHIV.C and SHIV.D
reproduced important characteristics of HIV-1 infection.
For an ideal virus in the NHP model system, recapitulation of key components of
each stage of infection is important, with acute HIV infection being paramount as the
host-pathogen balance may be established at the earliest stages of infection. In acute
HIV infection, peak VLs can reach greater than 106 – 107 c/ml with systemic virus
dissemination103,104. Following the exhaustion of target cells and the onset of adaptive
immune responses, a mean set point VL of between 10 3 – 105 c/ml is established, albeit
with substantial variation by individual103,104. Both SHIV.C and SHIV.D-infected RM
demonstrated the consistent timing and magnitude of early virus replication previously
seen with TF and other SHIVs, with peak viremia of between 105 – 108 c/ml within 7-14
days post inoculation67,71,76,84. Both SHIVs studied here established setpoint VLs of
between 103 – 106 c/ml through either 24 weeks post-infection or until initiation of cART
in all ten infected NHP, mirroring the viral kinetics of acute and early chronic HIV
infection.
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After early viral kinetics, a high priority for viruses used in cure studies is their
response to cART, in terms of the time to suppression after cART initiation, persistence
on longer-term cART, and viral rebound after cART interruption. Upon cART initiation,
all TF SHIV-infected NHP rapidly achieved virus suppression below assay limit of
detection, with the majority achieving undetectable levels within two weeks. This
timeframe is slightly more rapid than in HIV-1 infection, where cART containing an
integrase strand transfer inhibitor leads to viremia of less than 200 c/ml within one to two
months of cART initiation in most individuals34.
All 8 TF SHIV-infected RM maintained virus suppression with 24 weeks of cART,
with a single RM demonstrating a transient period of breakthrough viremia. Upon cART
interruption, the time to virus rebound was akin to that of chronic cART-initiating PLWH
in treatment interruption trials. All TF SHIV-infected RM rebounded between 5 and 22
days (mean = 12 days), which aligns well with the 85% of ATI trial participants who
rebound within four to 47 days (mean = 11 days) 38,39. We note the modest variability in
the reactivation rate of these animals, which is similar to the heterogeneity in time to
rebound in HIV positive individuals undergoing ATI. In sum, the viral kinetics of TF SHIV
infection before, during, and after cART provide a reasonable approximation of HIV-1
infection, with similar average set point VL and recapitulation of some of the variability
seen in PLWH.
The kinetics of TF SHIV infection prior to, during, and after cART differ from
SIVmac239 infection, which is one of the most frequently used NHP model systems.
SIVmac239 is a highly virulent clonal strain, which leads to a consistent and pathogenic
disease course in RM. By inducing a rapid progressor phenotype 65 characterized by
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accelerated disease progression, elevated inflammatory markers, and impaired immune
responses, SIVmac239 infection of RM can be harnessed for more efficient and
economical experiments with fewer animals and shorter duration to clinical endpoints.
Compared to TF SHIVs and the majority of people living with HIV, SIVmac239 infection
leads to higher peak (mean = 10 7-8 c/ml65,105 and set point (mean = 106 c/ml102) viremia in
comparison to both TF SHIV and HIV-1 infection. Further, SIVmac239 infection typically
requires more than four months of cART administration to achieve virus suppression,
which may impose financial and temporal constraints for latency and cure
experiments60,64.
The mechanisms underlying differences in TF SHIV and SIVmac239 viral kinetics
both off and on cART are likely primarily due to the enhanced virulence of SIVmac239.
Other related factors, including increased set point viremia, immune dysregulation,
microbial translocation, chronic inflammation, and/or infection of cellular subsets with
different half-lives and homeostatic programming60,102,63 may contribute to the differences
between viruses. We emphasize that SIVmac viruses have been robustly validated in
large cohorts of RM. In addition, SIVmac infection results in more consistent viral
kinetics and disease progression than SHIV infection, as a percentage of SHIV-infected
RM typically spontaneously control infection and do not progress to AIDS. Thus, when
selecting a virus for RM studies of HIV latency and cure, key differences in viral kinetics
on and off cART as well as pathogenesis and related disease progression should be
considered.
One inherent limitation of many NHP experiments, including the study reported here,
is the relatively short duration of both active viremia and cART administration. In
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contrast, the vast majority of people living with HIV and clinical trial participants are
viremic for years prior to cART initiation, leading to a greater diversity of replicating and
archived virus. Individuals are then treated with suppressive cART for multiple years
prior to reservoir evaluation, affording distinct reservoir dynamics with more time for the
extinction of shorter-lived infected cells and homeostatic or antigen-driven clonal
proliferation46. Given the importance of understanding what cells constitute the persistent
reservoir and developing strategies to counter clonal expansion, this limitation of NHP is
critical to recognize. Experiments that evaluate the effects of years of cART therapy on
SHIV and SIV-infected RM in the absence of an intervention, although logistically and
financially challenging, could address many of these concerns.
Despite relatively short times of virus replication prior to cART initiation in our two
experiments, SHIV infection prior to and on cART reflects several characteristics of HIV1 infection, including viral diversity, polyclonal rebound, and infection of long-lived cells.
Both SHIV.D and C-infected RM revealed significant pre-cART diversity, with a
maximum within-animal pairwise diversity of between 0.7-2.5%, allowing for
differentiation of distinct rebound virus populations. In people living with HIV,
recrudescent viremia after treatment interruption results from the systemic reactivation of
multiple distinct latently infected cells47–50. Similarly, TF SHIV rebound was largely
polyclonal, with 7 of 8 cART-treated RM demonstrating multiple genetically distinct virus
lineages replicating systemically within the first weeks of rebound, supporting a
multifocal model of rebound in both systems.
We found that the mean ca-DNA and ca-RNA measurements in chronic SHIV.D and
SHIV.C-infected RM were comparable to chronically HIV-infected cART-naïve patients
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(102-3 DNA copies/106 cells and 102-4 RNA copies/106 cells, respectively)106,107 . Ca-DNA
and ca-RNA in SHIV.D and C-infected RM decreased modestly in the first three to six
months following initiation of cART, consistent with the decay kinetics reported in studies
of cART-suppressed PLWH34,107,108. The magnitude of this decay reflects, at minimum,
the clearance of plasma virus, productively infected activated T cells with a short half-life
(less than two days), resting CD4 T cells with unintegrated virus, and likely shorter-lived
monocyte and macrophage-lineage cells43,22. The persistence of ca-DNA and RNA and
the rapid virus rebound seen after ATI indicates that the TF SHIV reservoir both persists
with modest diminution in number and transcriptional activity of infected cells after three
to six months of cART and has a slow decay rate on the order of months to years, as
seen in HIV-1 infection.
In SHIV.C-infected RM, we had a sufficient quantity of cells to characterize infection
of multiple cellular subsets in LNMC and PBMC; low cell yields prevented similar
analyses in SHIV.D-infected RM. We found that total resting memory CD4 T cells and
Tcm in particular were productively infected at a mean frequency of 10 3-4 copies/106 cells
throughout the course of the experiment (Figure 2.6D and F). TCM have been identified
as a major contributor to the latent reservoir in HIV+ cART-suppressed humans109. We
also found that TN, which given our sorting strategy includes memory stem T cells, were
productively infected in all SHIV.C-infected RM, albeit at a lower magnitude than other
subsets (Figure 2.6E). Our data suggest that TF SHIV infection leads to the
establishment of a latent reservoir comprised of genetically diverse and long-lived cells,
which persist through months of viral suppression and reactivate in the absence of
cART.
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We note some key differences between SHIV.D and SHIV.C-infected RM,
suggesting that SHIV.C lacks some characteristics that are desirable for a robust model
of HIV-1 latency. Most importantly, SHIV.C-infected animals spontaneously controlled
viremia below 103 c/ml post-rebound relatively frequently. In our study, rebound viremia
rose to 103-7 c/ml within four weeks post-ATI in all TF SHIV-infected RM and then fell to a
post-rebound set point, similar to SHIVs that demonstrate post-rebound virologic control
in some RM56,57. The emergence of adaptive (antibody24,6525,28,102 and CD8 T cellmediated23,110,111 immune responses have been shown to contribute to virologic control
and exert significant selection pressure in both SIV and HIV-1. Further, CD8 T cell
responses were reported to be integral for bNab-mediated virologic control in two
independent SHIV studies55,56. In other TF SHIV experiments, we have found that CD8
T cell depletion via administration of an anti-CD8 Ab leads to increases in plasma
viremia in some, but not all, spontaneous controller RM by one to two log 10 c/ml (data
not shown), suggesting that CD8 T cells may contribute to TF SHIV virologic control,
although off target effects of T cell depletion may also be a factor. As an alternate
explanation, SHIV.C infection may lead to lower levels of systemic virus replication postrebound than SHIV.D due to differences in intrinsic viral replicative capacity. The precART VL was 103-4 c/ml in three of four SHIV.C-infected animals. The post-rebound set
point VL was approximately one log10 c/ml lower and oscillated near the assay LOD of
83 c/ml. In parallel, we identified fewer distinct low-diversity lineages upon rebound in
SHIV.C in comparison to SHIV.D, which may be attributable to the limited duration of
viremia (16 weeks) prior to cART initiation and/or to the virus-host factors discussed
above. Sequences from post-rebound time points in RM with control revealed that
lineages present at first detectable rebound persisted over time in RM KM11 and KM65
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despite periods of spontaneous viremic control, supporting the hypothesis that virus
replication continued throughout this period at a level near our assay LOQ. At our
sampling depth, we did not find evidence of clearance and subsequent replacement of
the virus populations sampled at first detectable rebound in RM KM11 and KM65.
Comparisons of rebound and pre-cART sequences did not identify specific motifs
associated with virus control or persistence. Many RM that went on to experience postrebound control generally had less virus diversity at rebound, but it is unclear whether
the decreased virus diversity is a cause or an effect of enhanced immune-mediated virus
control.
In contrast, SHIV.D demonstrated many qualities that are desirable for a NHP model
of HIV-1 persistence on cART. SHIV.D infection here and in previous studies84
reproducibly led to high levels of systemic viremia over time. The viral dynamics and
reservoir biology of SHIV.D before, during, and after cART suggest that SHIV.D is a
promising NHP model for HIV-1 latency. SHIV.D encodes a well characterized and
CCR5-tropic32 subtype D Env, representing an epidemiologically relevant 30 and
pathogenically important component of the HIV-1 pandemic. Recognizing that subtype
D viruses have been associated with rapid disease progression and frequent emergence
of a CXCR4 or dual-tropic virus population, we analyzed sequences at the time point
immediately preceding cART for genotypes predictive of CXCR4 tropism. Using the
geno2pheno coreceptor algorithm, the majority of sequences in all RM were predicted to
be equally or more CCR5-tropic than the TF SHIV (data not shown), suggesting a lack of
progression to CXCR4 usage. Further, we did not see an enrichment of predicted
CXCR4-tropic viruses in RM DE33 and EJ94, which exhibited higher set point VLs and
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clinical disease progression. Importantly, we previously tested isolates from SHIV.Dinfected RM that succumbed to AIDS using phenotypic co-receptor tropism assays and
found that CCR5-tropism was retained84.
Two of the six SHIV.D-infected animals had coincident VL rise and clinical
deterioration. At necropsy, pathologic analysis revealed profound systemic CD4 T cell
depletion and high viral burden in various lymphoid tissues in both RM and in PBMC
from RM EJ94 (Figure 2.4A-C). Severe CD4 T cell depletion was identified in in gutassociated lymphoid tissue (GALT) from both RM (Figure 2.4A); this tissue has been
shown to harbor the largest number of CD4 T cells of any site in the body112. To date, TF
SHIV pathogenesis has been documented in acute and early infection, where gut and
lymphoid CD4 T cells are diminished, while peripheral CD4 T cells are relatively
preserved85. This degree of CD4 T cell depletion within one to two years of infection in
two of six RM suggests rapid pathogenesis of SHIV.D infection.
Our study has several limitations in addition to those described above. First, one of
six SHIV.D-infected RM (FT42) spontaneously controlled infection after 42 weeks of
infection. Further, while all SHIV.C-infected RM rebounded, three of four did not maintain
persistent plasma viremia following ATI. As delineated in Figure 2.8, virus control postrebound was associated with fewer variants and less diversity at rebound, which likely
reflects the inability of the virus to replicate sufficiently to escape from host-control. The
SHIV.C experiment also differed from the SHIV.D experiment in that the SHIV.C-infected
RM were actively viremic for a shorter duration (16 weeks versus 37-85 weeks) and
were inoculated with a stock that was 10-fold less infectious. These factors may have
contributed to the frequency of post-control rebound in the SHIV.C-infected RM.
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Altogether, the frequency of pre and post-cART viremic control of TF SHIVs, in particular
SHIV.C-infected RM, is a limitation for their use in cure studies.
Other study limitations include the sample size in both our SHIV.D and SHIV.C
experiments, which was small (six RM and four RM per study, respectively), limiting the
statistical power of our analyses. Additional studies in larger cohorts will be important to
validate these findings. In addition, the duration of cART during our studies was limited
to 24 weeks and therefore was insufficient to observe reservoir decay in longer lived
cellular reservoirs, such as resting memory CD4 T cells, which have a half-life of months
to years40. As we did not longitudinally sample tissues from the central nervous system
and other possible anatomical reservoirs such as lymphoid tissues, which harbor the
majority of CD4+ T cells in HIV-1-infected individuals, we were unable to characterize
the viral reservoir dynamics at these sites43,113. Moreover, the quantity of cells collected
after three to six months of cART in both SHIV.D and SHIV.C-infected RM were
inadequate to conduct a more complete reservoir analysis, such as characterizing the
genetic intactness and replication-competence of reservoir viruses using whole genome
sequencing or viral outgrowth assays40.
In summary, we have validated two novel TF SHIVs as relevant viruses in the RM
model of HIV-1 latency. The characteristics of SHIV.D.191859, and to a lesser extent,
SHIV.C.CH848, during chronic infection, cART administration, and upon treatment
interruption suggest that they are promising reagents for a SHIV model of HIV-1 latency
and that they are suitable for studies of HIV-1 reservoir biology and pathogenesis. Our
findings demonstrate that the TF SHIV-macaque model has broad applications for
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elucidating mechanisms of HIV persistence and evaluating a range of eradicative and
suppressive strategies.
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Abstract
SHIVs encoding transmitted/founder (TF) HIV-1 Envs successfully infect rhesus
macaques (RM) and confer consistent early viral kinetics. SHIV.CH505 encodes a TF
clade C Env of significant interest, but it replicates inconsistently over time in a fraction
of RM. Here, we develop and validate a minimally adapted SHIV.CH505 with enhanced
replication. In two distinct cohorts of outbred SHIV.CH505-infected RM (n = 25 RM total),
we identified a pattern of 4-7 virus mutations that arose and evolved towards fixation
with greater frequency in RM with higher (>10 3 c/mL) vs. lower setpoint VLs using
longitudinal sequencing. Two sequential limited in vivo passage experiments in which
early SHIV.CH505-infected RM plasmas were intravenously inoculated into uninfected
RM demonstrated that the signature mutation variants rapidly went to fixation and were
associated with consistently high VLs (103-5 c/ml).
A library of 15 SHIV.CH505 infectious molecular clones (IMC) containing the
signature mutations alone or in combination were tested for replication in primary RM
CD4 T cells. Results revealed that IMCs containing single and combination mutations
replicated 2-4-fold and 3-46-fold better than the parental SHIV.CH505, respectively, but
without a clearly dominant variant. An in vivo competition experiment of the 8
combination clones in 3 outbred RM showed that a single IMC containing 5 mutations,
termed 5MA, outcompeted in all 3 RM, comprising 76, 95, and 98% of all viruses at 4
weeks post-infection. When tested in direct in vivo competition with the parental
SHIV.CH505 in 4 RM, 5MA rapidly outcompeted the parental SHIV, representing 9799% of all viruses by 4 weeks post-infection. In all 7 RM in which IMC 5MA
predominated, setpoint VLs were consistently high (between 103-5 c/ml). Neutralization
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assays suggest that the 5MA IMC maintained its closed, native Env structure better than
other clones that replicated well in vitro, but did not outcompete in vivo.
5MA’s component mutations lie within or proximal to the CD4 and CCR5 binding
sites, indicating that signature mutations confer possible effects on virus entry or are
reversions to Group M consensus. In vitro entry assays confirmed that 5MA exhibited
significantly increased entry into rhesus CD4 and CCR5-expressing cells compared to
the parental SHIV.CH505. In summary, we used a combination of in vivo passage and
competition experiments and in vitro assessments to identify and validate a minimally
adapted SHIV.CH505 with enhanced virus replication that may have broad applications
for HIV research in RM.
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Introduction
The non-human primate (NHP) model employing rhesus macaques (RM) is an
essential component of HIV research initiatives67,71,78,77. Chimeric simian-human
immunodeficiency viruses (SHIVs), which encode an HIV-1 envelope glycoprotein (Env)
in the context of macaque-adapted simian immunodeficiency virus structural and
regulatory elements, have been extensively used to study the role of HIV-1 Env in virushost interactions, transmission, and pathogenesis. SHIVs have particular importance as
reagents in studies testing strategies that engage Env, such as broadly neutralizing
antibodies (bNabs) and antibody-based vaccines55,57,56,79.
One issue associated with SHIV development is that the majority of unadapted
SHIVs do not yield persistent viremia over time 67,71,76. Serial transfer, or passage of
blood and tissues from a SHIV-infected to a naïve RM, has historically been successful
in overcoming this limitation and conferring increased viral infectivity and pathogenicity.
Passaged SHIVS, including the dual-tropic SHIV 89.667 and CCR5-tropic SHIVs 162P371
and AD876, have been primarily used for evaluating vaccines and broadly neutralizing
antibodies (bNAbs) in preclinical studies. Importantly, passaged SHIVs exhibit several
key characteristics of HIV-1 infection, such as systemic CD4 T cell depletion and
induction of adaptive immune responses71,76.
A limitation of previous iterations of passaged SHIVs is that the encoded Envs
were often sourced from individuals who had progressed to AIDS 114,115, minimizing their
relevance to transmitted/founder (TF) HIV isolates. Multiple reports suggest that TF
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isolates have a unique signature compared to non-transmitted isolates, such as enriched
Env content and increased interferon-beta resistance17,80. Further, passaged SHIVs
exhibit substantial alteration of the parental HIV-1 Env sequence, thereby limiting their
direct relevance to circulating HIV isolates78,13,71. An additional issue associated with
previous iterations of SHIVs is that a subset of infected RM spontaneously control
viremia to below 103 viral c/ml during chronic infection despite the increased
pathogenicity and infectivity conferred by serial passage 76,56
Recently, we reported the development of a novel strategy to generate designer
SHIVs encoding native TF or primary Envs with Tier 2 neutralization sensitivity, hereafter
referred to as TF SHIVs84. A study from Overbaugh and colleagues found that a singular
residue (39)116 in rhesus CD4 domain 1 (D1) mediates functional differences in the ability
of macaque and human CD4 molecules to bind HIV-1 Env. Env residue 375 in the Phe43 binding pocket, which is adjacent to the CD4 binding site, was found to be under
strong selection pressure across primate lentiviruses, suggesting that mutagenesis of
residue 375 could lead to increasing binding to rhesus CD4. Substitution of a single
amino at Env position 375 resulted in the ability of various HIV-1 Envs to bind similarly to
both rhesus and human CD473, enabling effective in vitro and in vivo infection of RM
while preserving the protein conformation of the parental Env. TF SHIVs are CCR5tropic and consistently confer productive infection, high peak viremia, and desirable early
viral kinetics84.
Some TF SHIVs, however, replicate to lower set point VLs (VL) or are
spontaneously controlled in a subset of RM in a manner similar to their predecessors.
One such example is TF SHIV.CH505, which encodes a clade C TF Env and has been
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used as a reagent for a NHP model of HIV-1 infection for numerous applications,
including vaccine studies84,85,88,89,117. The CH505 virus was sampled from an African man
who later developed CD4 binding site-directed broadly neutralizing antibodies (bnAbs) at
around 1 year post-infection; an approach to elicit similar antibodies via vaccination in
humans has been described118 and the Env-antibody co-evolution has been
recapitulated in RM infected with SHIV.CH505 119.
The goal of our study was to use limited passage to identify a more fit version of
this key reagent. We set out to use a reductive approach to serial passage, where we
evaluated candidate infectious molecular clones (IMCs) in an in vivo competition setting,
enabling the best replicating viral variant to outcompete in its host.
Here, we performed a series of in vitro and in vivo studies to identify a minimum
number of mutations that confer enhanced SHIV.CH505 kinetics with the goal of
generating a robust reagent for the SHIV-macaque model of HIV-1 infection. We
assessed the impact of candidate mutations on viral fitness in vivo and in vitro in primary
rhesus CD4 T cells, as well as neutralization and entry assays. Our results suggest that
we have generated a minimally adapted SHIV.CH505 with a conserved Env
conformation that enhances viral kinetics in vitro and in vivo. This novel reagent, termed
SHIV.CH505.v2, has broad applications for a non-human primate model of HIV-1
infection. These results identify enhanced entry as the mechanism by which
SHIV.CH505.v2 was adapted to a novel host.
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Materials and Methods
Nonhuman Primates
Indian-origin RMs were housed at Bioqual LLC according to the standards of the
Association for Assessment and Accreditation of Laboratory Animal Care. All
experiments were approved by the Penn Animal Care and Use Committee (ACUC). All
animals were tested and found to be negative for described SIV controller alleles MamuA*01, B*08, and B*17. Animals were sedated for SHIV inoculations, peripheral blood
draws, and biopsies, as previously described 84. Whole blood from animals was
processed using centrifugation as described in 84. PBMCs were isolated using FicollPaque (GE Healthcare) gradient centrifugation. Plasma was clarified by centrifugation
for 15 min at 3000 rpm, frozen, thawed, and then subject to viral RNA extraction as
described below. SHIV VL levels in plasma were determined by quantitative real-time
reverse-transcription PCR of SIV RNA by the Duke University IQVAC Core Laboratory
as previously described120.

Construction and Characterization of Point and Combination SHIV.CH505 Clones
SHIV.CH505 clones containing signature mutations in isolation were generated and
viral stocks were made via transfection of 293T cells as described in

84.

Briefly, amino

acid change-conferring substitutions were placed into the SHIV.C.CH505.3C backbone
using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs). Primers were
designed according to the NEBaseChanger tool (https://nebasechanger.neb.com). All
clones were sequenced in their entirety to verify that only desired mutations were
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present in the constructs. 293T cells were transfected as described in 84. Briefly, 6 ug of
plasmid DNA and 18 ul of FuGENE 6 (Promega) transfection reagent were first added to
a tube containing 0.5 mL of serum-free DMEM (Gibco) and then added to a pre-seeded
Petri dish containing 3.6X106 293T cells in 10 mL of complete media (DMEM (Gibco),
100 U/ml pen/strep (Gibco, and 10% FBS (Gibco)) that had incubated at 37C overnight.
48 hours later, supernatants containing virus were spun at 3000 RPM for 8 minutes to
pellet cellular debris and then aliquoted.
The virion content of viral stocks was quantified using the p27Ag 96-well ELISA kit
from ZeptoMetrix; the manufacturer’s instructions were followed with no alteration of the
recommended protocol. Titration on TZM-bl cells was performed as described in

84;

briefly, 15,000 cells were seeded in a flat-bottom 96-well tissue culture plate in
quadruplicate and incubated at 37C overnight. The following day, fivefold dilutions of
virus stock in sextuplet were plated, beginning with a virus stock dilution of 1:5 in
complete cell media (DMEM (Gibco), 100 U/ml pen/strep (Gibco), 6% FBS (Gibco), and
40 ug/ml DEAE-Dextran (Thermofisher)). After 48 hours of incubation at 37C, media was
removed, cells were fixed by pipetting 100 ul of fixing solution in each well (500 ml PBS,
4 ml glutaraldehyde, 11 ml formaldehyde). After 10 minutes, cells were washed 3X with
PBS and 100 ul of X-gal staining solution was placed into each well. After 3 hours, cells
were washed 3X with PBS and the number of blue cells in each well was counted using
an automatic counter. The average number of blue cells in two consecutive dilutions
across all 4 quadruplicates was determined and standardized to the input virus volume;
the final titer was the mean of 2 consecutive titers.
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Stocks of SHIV.CH505 clones containing signature mutations in combination
were generated as described in

84.

Briefly, 8 candidate Envs containing variations of

signature mutations were synthesized by Synbio Technologies and were cloned into the
SHIV.3C backbone using the BsmBI restriction sites at the 5’ and 3’ end of the CH505
Env cassette and then ligated together using T4 ligase (NEB). 8 plasmids encoding fulllength SHIV.CH505 combination clones were used to transfect 293T cells as described
above and in 84. Infectivity on TZM-bl cells and virion content was determined as
described above. The infectivity of CH505 combination clone stocks ranged between
1.18X10-3 and 9.00X10-4 IU/particle, respectively, as determined on TZM-bl cells.

Generation of CH505.5MA and TF Barcoded Stocks (Study 5)
Barcoded stocks of SHIV.CH505.5MA and SHIV.CH505.TF were generated as
described in 84,121. Briefly, the CH505.TF and CH505.5MA Envs were cloned into a
SHIV.3C backbone containing NotI at the barcode insertion site using the BsmBI
restriction sites at the 5’ and 3’ end of the Env cassette and SHIV.3C backbone and then
ligated together using T4 ligase (NEB). The barcode inserts consisted of single stranded
forward and reverse barcoded templates consisting of 10 random bases each. The
forward and reverse barcode primers were heated to 95°C and then cooled at a rate of
1.5°C/min to enable annealing. SHIV.CH505.TF.barcoded (BC) and
SHIV.CH505.5MA.BC were digested with NotI. DNA was purified and the digested
viruses and primer dimers were ligated at 16°C overnight. The ligated, barcoded viruses
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were transformed into Stbl2 cells. The plasmid library was DNA extracted and barcodes
were sequenced via the Illumina platform. Stocks were made as described above.
Infectivity on TZM-bl and virion content was determined as described above. The
infectivity of SHIV.CH505.TF.BC and SHIV.CH505.5MA.BC stocks on TZM-bl cells were
1.86 and 4.3X10-4 IU/particle, respectively. To assess the infectivity of SHIV.CH505.TF
and SHIV.CH505.5MA on primary rhesus CD4 T cells, activated cells were plated at a
density of 3×105 cells/well in 96-well flat-bottom tissue culture plates in complete primary
cell culture media (RPMI (Gibco) with 15% FBS (Gibco), 100 U/mL penicillin–
streptomycin (Gibco), 30 U/ml IL-2, and 40 µg/mL DEAE–dextran (Thermofisher)).
Fivefold dilutions of virus stock in sextuplet were plated, beginning with a virus stock
dilution of 1:5; the virus stock in each well was diluted to a total of 60 ul of complete
primary cell culture media as described above. The virus mixture was incubated for 3 h
at 37°C. Complete media was added to bring the total volume to 0.25 mL in each well,
after which the plate was incubated at 37°C. p27 antigen measurements were made at
day 4 and TCID50 was calculated by using the Reed Muench method. The infectivity of
viral stocks was determined via titration on TZM-bl cells as described above and in 84.
The infectivity on primary rhesus CD4 T cells ranged between 1.83X10-4 and 5.32X10-5
IU/particle, which is similar to other TF SHIVs84. These stocks were used for the
experiments described in Study 5; no barcode sequencing of RM samples, however,
was performed in this study.
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Study 3 Inoculum
For passage 1, RM 5695 was intravenously inoculated with a mixture of plasma
containing 200 ul from each of the following RM and timepoints: RM 6069 and 6070 at
10 and 20 WPI and RM 6072 at 4, 10 and 20 WPI. For passage 2, RM 5181 was
intravenously inoculated with 200 ul of plasma from RM 5695 at the following timepoints:
4, 8, 16, and 24 WPI.

Study 4 Inoculum
The Study 4 inoculum was prepared by adding 10 ng of each of 8 candidate
CH505 combination clones, with the stock containing 80 ng total per animal. The stock
was then diluted in complete media (RPMI (Gibco) with 15% fetal bovine serum (FBS,
Gibco), 100 U/mL penicillin–streptomycin (Gibco)) to a volume of 1 mL per animal. RM
T646, 5593, and 150250 were inoculated with the CH505adapted stock mixture.

Study 5 Inoculum
The Study 5 inoculum was prepared by combining 2 stocks: SHIV.CH505.5MA
and SHIV.CH505.TF. 2 inocula were prepared, with inoculum 1 (30 ng total) containing
15 ng and the inoculum 2 (300 ng total) containing 150 ng of each variant, respectively.
Virus stocks were prepared using the same medium as in Study 4. The 300 ng stock
mixture was sequenced via single genome sequencing as described below and diluted
1:10 to make the 30 ng virus stock mixture; each inoculum vial was diluted to a volume
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of 1 ml per animal. RM T276 and T277 were inoculated with 30 ng and RM T278 and
T279 were inoculated with 300 ng of the Study 5 inoculum, respectively.

Viral Single Genome Sequencing
Single-genome full-length gp160 env sequences were generated as described in
84.

Briefly, 20,000 viral RNA copies were extracted from plasma virus using the Qiagen

BioRobot EZ1 Workstation with EZ1 Virus Mini Kit v2.0 (Qiagen). Eluted vRNA was
subsequently used as a template for cDNA synthesis and reverse-transcribed using the
reverse primer SHIV.Env.R1 (5′- TACCCCTACCAAGTCATCA-3′) and SuperScript III
reverse transcriptase (Invitrogen Life Technologies). cDNA was serially diluted in a 96well plate (Applied Biosystems) to identify the dilution at which <30% of wells contained
PCR amplicons of the correct size. The SHIV gp160 env genome was amplified via
nested PCR with primers as follows: first round forward primer SHIV.Env.F1 (5′CGAATGGCTAAACAGAACA-3′), second round forward primer SHIV.Env.F2
(CTACCAAGGGAGCTGATTTTC), first round reverse primer SHIV.Env.R1 (5′TACCCCTACCAAGTCATCA-3′), and second round reverse primer SHIV.Env.R2 5’TATTTTGTTTTCTGTATGCT-3’). PCR conditions were used as follows for the first
round of nested PCR: 94°C, 2 min; 37x [94°C, 20 sec; 55°C, 30 sec; 68°C, 3 min 30
sec]; 68°C, 10 min. For the second round of nested PCR, the PCR conditions were as
follows: 94°C, 2 min; 42x [94°C, 20 sec; 54°C, 30 sec; 68°C, 3 min 30 sec]; 68°C, 10
min. Amplicons were sequenced via the MiSeq platform (Illumina). Raw reads were
aligned to the SHIV.CH505 reference using Geneious R9. Sequences that contained
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mixed bases at a frequency of >25% per nucleotide position were excluded from further
analysis.
Sequences from plasma virus from RM 6069, 6070, and 6072 (Study 1) were
generated at 4, 10 and 20 WPI. Sequences from RM in Study 2 were generated at 52
WPI. Due to the limited number of available sequences, which was attributable to low VL
at the time of sampling in a number of RM, an 100% penetrance threshold was used to
identify virus populations that had one or more non-synonymous AA substitutions in Env.
Sequences were re-examined using 50% as the penetrance threshold for nonsynonymous AA substitutions, which resulted in similar findings (data not shown).
Sequences from plasma virus from RM 5695 (Study 3) were generated at 2, 4, 12, 16,
24, and 48 WPI. Sequences from plasma virus from RM 5181 (Study 3) were generated
at 2, 8, 12, and 24 WPI.

Viral Deep Sequencing
Approximately 103-105 viral RNA copies were extracted from plasma and cDNA
was generated as described above and in 84. The volume of cDNA required to sample
102-3 individual copies was determined and used as the input for bulk PCR amplification,
with amount of plasma vRNA copies in the initial sample being the limiting factor. Nested
bulk PCR conditions were used as follows for the first round of nested PCR: 94°C, 2 min;
37x [94°C, 20 sec; 50°C, 30 sec; 68°C, 1 min]; 68°C, 10 min. For the second round of
nested PCR, the PCR conditions were as follows: 94°C, 2 min; 42x [94°C, 20 sec; 68°C,
30 sec; 68°C, 1 min]; 68°C, 10 min. The primers used were as follows: first round
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forward primer CH505adapted F1 5’-TGCTCCAGCTGGTTATGCG-3’, second round
forward primer CH505adapted F2 5’-TCGTCGGCAGCGTCAGA
TGTGTATAAGAGACAGTGTCAGCACAGTACAATGTACACA-3’, first round reverse
primer CH505adapted R1 5’-TGTTATGTTTCCTGCAATGGG-3’ and second round
reverse primer CH505adapted R2 5′-GTCTCGTGGGCTCGGAGATGTGTA
TAAGAGACAGATTGCTCGTCCCACCTCCTG-3′.
Bulk PCR reaction products were multiplexed and sequenced via the MiSeq
platform (Ilumina). The frequency of variants most similar to the 8 candidate
CH505adapted clones were determined using a software analysis pipeline, incorporating
open source software with custom scripts written in python, bash, and R. Raw reads
were aligned to the SHIV.C.CH505 T/F reference sequence using bowtie2 with default
parameters.

Reads that had more than 7 mismatches to the reference genome

were excluded from downstream analysis, to allow for reads with all 6 mutations
identified upstream (V255I, N279D, K302N, Y330H, N334S, H417R) plus one additional
mismatch. Each remaining read's bowtie alignment was used to extract the nucleotides
at the six variant locations. The 6 nucleotides of interest were used to classify each
read, and each sample was condensed to a summary of how many reads had each
particular combination of nucleotides/variants. Frequencies of variants were calculated
against the number of reads passing all filters.

Rhesus CD4 T Cell Isolation and Activation
Rhesus CD4 T cells were isolated as described in

84

. Briefly, rhesus PBMC were

combined with magnetic CD4 MicroBeads (Miltenyi Biotec) and processed according to
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manufacturer’s instructions. Antibiotin MACSiBead particles loaded with biotinylated antiCD2, CD28, and CD3 antibodies (T-cell activation/expansion kit from Miltenyi Biotec)
were combined with isolated rhesus CD4 T cells as described by the manufacturer. The
isolated CD4+ cells were cultured in complete growth medium (RPMI with 15% fetal
bovine serum (Hyclone), 100 U/mL penicillin–streptomycin (Gibco), and 30 U/mL IL-2
(Prometheus Laboratories) for 5-6 days.

SHIV Replication in Primary Rhesus CD4 T Cells.
SHIV infection of primary rhesus CD4 T cells were performed as described in 84.
Each SHIV variant was normalized to 300 ng of input virus per well and combined with
2X106 rhCD4 T cells in complete RPMI 1640 growth medium containing 40 µg/mL
DEAE–dextran and 30 U/ml IL-2 to a total volume of 1 mL per well in a 24 well-plate.
The cell and virus mixtures were incubated at 37 °C in 5% CO 2 for 4 h and subsequently
washed 3 times with 10 mL of complete RPMI growth medium without DEAE-dextran
and IL2. Cell and virus mixtures were each resuspended in 1 mL of complete RPMI1640
growth medium and 30 U/ml IL2 in 24-well plates and cultured for 9 days. Supernatants
were collected on days 0, 3, 6, and 9 for p27 antigen measurement. For the summary
graphs shown in Figure 3.5, the first timepoint at which the replication of TF.CH505 was
>5 or 10 ng/ml for point and combination clone experiments, respectively, was used,
reasoning that this timepoint was early enough to 1) allow for comparison between
independent experiments given differences in time to peak replication, 2) mitigate the
confounding factors of decreased cell viability and depletion of available target cells that
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occur towards of the tail end (~d9+) of the experiment, and 3) capture differences in viral
replication rates that perhaps would be most apparent at earlier timepoints.

TZM-bl Neutralization Assay
TZM-bl neutralization assays were performed as described in

84.

Briefly, TZM-bl

cells were seeded at 10,000 cells per well. After 24 hours, selected antibodies (Ab) were
serially diluted 5-fold and mixed with 4,000 IU of virus stock as measured on TZM-bl
cells. Antibody-virus mixtures were co-incubated for 1 h and then added in triplicate to
pre-seeded TZM-bl cells. After 48 hours, cells were simultaneously lysed and mixed with
luciferase substrate via addition of Bright-Glo (Promega). Background-corrected
luciferase activity for each sample was determined as described in

84;

IC50 values were

calculated using the variable slope function in Prism (v7.0). All monoclonal antibodies
(PG121, VRC01, 3BNC117, PGT145, 4E10, 17B, 3869) were obtained from the NIH
AIDS Reagent Program.

ZB5 Entry Assay
ZB5 cells were propagated and infected as described in 84. Briefly, cells were
propagated in complete growth medium containing DMEM (Gibco) + 10% FBS (Gibco) +
100 u/ul pen/strep (Gibco); medium was supplemented with 5 μg/mL blasticidin (Thermo
Fisher Scientific) to select for rhCCR5 expression and 5 μg/mL puromycin (SigmaAldrich) to select for cells expressing rhCD4.
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The ZB5 entry assay was performed in triplicate. Cells were seeded at 1×10 4 per
well in 100 ul of complete media in 96-well plates and incubated overnight. Virus stock
dilutions were made to final concentrations in complete DMEM + 40 μg/mL DEAE–
dextran to achieve 0.5 ng p27 antigen/well. Day 1 medium was removed and cells were
incubated at 37 °C with the virus inoculum diluted in complete growth medium for 48h.
Cells were lysed with Bright-Glo (Promega) 48 h post-infection, and RLUs were
measured on a Luminoskan Ascent luminometer (Thermofisher).

Results
Identification of a signature of enhanced SHIV.CH505 viral kinetics
The determinants of viral setpoint in HIV-1 infection are multifactorial, balancing
virus fitness and host immune pressures. Within the SHIV-macaque model, and
SHIV.CH505 specifically, the viral determinants of replication fitness are likely complex
and context-dependent. To this end, we set out to identify a common mutational
signature associated with enhanced viral fitness by comparing virus evolution in
SHIV.CH505-infected RM with higher versus lower VLs over the first six months of
infection.
SHIV.CH505 infection results in a range of set point VLs; across 4 published
studies, 21% of SHIV.CH505-infected RM (n=33) spontaneously controlled plasma
viremia to around or below 102 c/ml by 12 weeks post-infection85,88,89. Of the remaining
RM, 52% exhibited VLs of 102-3 c/ml at the same time point, while 27% exhibited higher
VLs of 104-5 c/ml. 3 RM from this aggregate cohort (6069, 6070, and 6072, Study 1)84
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that exhibited high VL (104-6 c/ml) for 36-40 weeks were analyzed (Figure 3.1) 2 RM in
this cohort were euthanized at 36-40 WPI due to progression to AIDS. The remaining
RM 6072 maintained persistent viremia of 10 3-4 c/ml for over 52 weeks.
Single genome sequences (SGS) of gp160 env were generated from longitudinal
plasma samples (4, 10 and 20 WPI) for the 3 RM (Figure 3.1A, total number of
sequences = 287, median number of sequences per animal time point = 41). SGS of
plasma virus limits in vitro recombination, allows linkage across the amplified region, and
accurately characterizes the relative frequency of the diverse, circulating quasispecies 15.
While mutations that arise in one RM are often a result of adaptation to a host-specific
immune response, mutations that are shared across multiple outbred RM are likely to
reflect a virus-specific benefit. A limited number of shared mutations were common to
the 3 RM over the first 5 months of infection. Thus, majority mutations that were present
in 50% of sequences at 20 weeks post-infection (WPI) from all 3 RM were collated. 2
mutations, N334S and H417R, arose early in all animals, representing a majority of
sequences in all RM by week 10 and increasing to 77-100% penetrance by 20 WPI. 4
additional mutations (N130D, N279D, K302N, and Y330H) arose later, in the presence
of N334S and H417R. By 20 WPI, mutations K302N, Y330H, N334S, and H417R were
present in 77-100% of sequences in all 3 RM, with the exception of K302N (51%
prevalence) in RM 6072. Thus, 6 conserved sites of selection pressure in gp160 env
(130, 279, 302, 330, 334, and 417) were identified in all 3 RM with higher VL (Figure
3.1A and B).
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Confirmation of a mutational signature of sustained SHIV.CH505 viremia
Next, we examined virus sequences from an orthogonal cohort of 45
SHIV.C.CH505-infected RM (Study 2) to assess if the mutational signature described in
Study 1 was common across multiple cohorts of RM. In this study, 28 RM were
vaccinated with a CH505-based Env DNA vaccine and 17 control RM received either an
adjuvant or no intervention118,117. All RM were subsequently challenged with the
autologous SHIV.CH505; 40 of 45 RM became infected. Vaccine administration had a
modest effect (~1 log10) on VL at several early timepoints (2-9 WPI); after 9 WPI,
however, no significant difference in VL among the groups was detected. Plasma virus
from 22 of 40 infected RM was sequenced via SGS at 52 WPI to mitigate the effect of
these early differences in VL and enable combining all RM into a single group. 5 of these
22 RM maintained high (>10 4 c/ml) set point VLs at 32 WPI, while the remaining 17 RM
had lower VLs, ranging from <50 to 10 3 c/ml; this timepoint was selected due to lack of
consistent sampling across all RM at later timepoints (Figure 3.2A). We then assessed if
the prevalence of signature mutations was enhanced in high versus low VL RM
(summarized in Figure 3.2B, which describes mutations that appeared with 100%
penetrance in each RM).
Similar to the Study 1 RM, a higher frequency of the identified signature
mutations K302N, Y330H, N334S, and H417R was identified in high vs. low VL RM at
this time point. These 4 substitutions were 17-56% more prevalent in high vs. low VL
RM, depending on mutation (Figure 3.2B). The prevalence of mutations N130D and
N279D, which were identified in Study 1, was modestly increased in high versus low VL
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RM (20% versus 6%, Figure 3.2B). Thus, a similar genetic signature of sustained set
point viremia was identified in a second cohort of RM.

SHIV.CH505 passage results in enhanced viral kinetics
Limited in vivo passage, or serial transfer of blood or infected tissues from an
infected to naïve RM, has been used historically to improve the viral kinetics of SHIVs
that initially replicated poorly67,71,76. We performed a limited passage experiment in 2 RM
(Study 3) using plasmas from early infection from 3 previously described RM (Study 1) to
test whether the identified signature mutations would outcompete wildtype virus,
determine the kinetics of the shifts in viral populations, and determine if earlier evolution
of signature mutations led to consistently higher VLs. The first animal, RM 5695 was
inoculated with a mixture of high VL plasma from early time points (4, 10 and 20 WPI,
see methods) from the 3 RM described in Study 1 (Figure 3.3A); we termed this
experiment passage 1 (P1). The inoculum contained a greater percentage of variants
from earlier timepoints due to higher VL at the time of sampling, with 7% and 69% of
variants originating from 4 and 10 WPI, respectively; plasma virus at 4 WPI was similar
to CH505.TF in terms of sequence (Figure 3.1A).
RM 5695 exhibited high peak viremia (105-6 c/ml), maintained persistent viremia
(103-4 c/ml) for over a year and was euthanized at 64 WPI due to progression to AIDS
(Figure 3.3A). Longitudinal env gp160 SGS were generated using plasma from 2 to 48
WPI (Figure 3.3B, total number of sequences = 450, median number of sequences per
animal = 42).
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At 2 WPI, the only 2 signature mutations sampled in most or all of the sequences
in RM 5695 were N334S and H417R, similar to what was sampled in the inoculum RM at
10 WPI; this finding was unsurprising given that viruses from this timepoint were
overrepresented in the inoculum. Sequences at 4 WPI revealed strong evidence for a
selection bottleneck between 2 and 4 WPI; by this time, 100% of sequences contained
the K302N, Y330H, N334S, and H417R signature mutations (Figure 3.3B).
A slightly different pattern of sequence evolution arose in RM 5695 over time in
comparison to Studies 1 and 2. By 12 WPI, 100% of circulating plasma viruses in RM
5695 contained the 6 signature mutations identified in Study 1 and 2 (N130D, N279D,
K302N, Y330H, N334S, H417R) in addition to a novel mutation, V255I (62% prevalence,
Figure 3.3B and C). All signature mutations persisted, and at 24 WPI, 94-100% of all
circulating virus contained all 6 previously identified signature mutations. The frequency
of V255I also increased at this timepoint (77% prevalence). Interestingly, V255I was
present in only a minority (44%) of sequences from Study 1 RM 6069 at 20 WPI and was
not found in any other sequences from Study 1 and 2 RM (Figures 3.1 and 3.2). By 48
WPI, only 1 signature mutation, N130D, substantially decreased in frequency in RM
5695 (43% prevalence, Figure 3.3B and C).
The second passage animal, RM 5181, was inoculated with plasma from RM
5695 from early time points (4-24 WPI, Figure 3.3A). The passage 2 (P2) inoculum was
both highly enriched for all 6 signature mutations and genetically diverse, with the vast
majority of variants being divergent from wild type SHIV.CH505. As with RM 5695, serial
passage led to enhanced longitudinal viral kinetics in this RM. RM 5181 exhibited slightly
higher VLs than RM 5695 at each timepoint after 12 WPI (2-15-fold difference), and
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exhibited high set point viremia (10 4-5 c/ml) for over a year (Figure 3.3A), at which point
RM 5181 developed symptoms consistent with AIDS and was euthanized.
In RM 5181, by 2 WPI, 93-100% of plasma virus variants contained the 6
signature mutations; in addition, most contained the V255I mutation (72% prevalence,
Figure 3.3B and C), which rapidly went to complete fixation by 8 WPI. Thus, all 6
signature mutations achieved fixation early and remained at fixation in both passage
animals.

Signature mutations are located in sites predicted to interact with rhesus CD4 and
CCR5
To better understand the putative roles of signature mutations, all 7 residues (130,
255, 279, 302, 330, 334, 417) were modeled onto the BG505 SOSIP Env monomer
using PyMOL (Figure 3.4). Of these, all residues except for 130 were predicted to be
located in or adjacent to the rhesus CD4 and CCR5 binding sites. Env residue 130 is
located at the N-terminus of the V1 loop near the apex of the Env trimer and is not
proximal to described CCR5 and CD4 binding sites (Figure 3.4). In addition, N130D was
no longer present in the majority of sequences in P1 RM 5695 by 48 WPI and was not
selected for in the cohort of high VL RM examined in Study 2; due to these reasons, it
was excluded from further consideration.
The remaining 6 signature mutation residues were found to be located in the gp120
bridging sheet (255, located in C2 84 and 417122, located in V4), which links the inner and
outer domains of gp120 Env upon binding to CD4, in the CD4 binding site (279)123, and
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at the N and C-termini of V3 (302 and Y330, respectively)66. Residue 334, which is
located in C3, is also located adjacent to the CD4 binding site66. Some signature
mutations (K302N, Y330H, N334S) encode AAs that are highly conserved (70-96%66)
across all HIV-1 isolates; mutagenesis of the remaining 3 Env residues (255 124, 279125,
417126,127) in the context of HIV-1 IMCs modulated binding and/or entry into CD4 and
CCR5-expressing cells in several studies.

In vitro replication of SHIV.CH505 clones
To determine the contribution of individual signature mutations to virus
replication, full-length SHIV.CH505 IMCs containing each of 6 signature mutations in
isolation were generated and shown to be infectious in vitro. The single mutation clones
were used to infect primary rhesus CD4 T cells in at least 3 independent experiments
(Figure 3.5A). Figure 3.5A shows a representative experiment testing all single mutant
clones against the TF. With the exception of V255I, all of the signature mutations in
isolation conferred minimal benefit, with a consistent non-significant increase in
replication over wildtype SHIV.CH505 (median = 1.8 to 3.3-fold increase in p27, p=1,
Dunnett’s multiple comparisons test) across 2-3 independent experiments, Figure 3.5A.
The IMC containing V255I, in contrast, consistently exhibited significantly worse
replication than the parental TF virus (median = 29.4-fold decrease in p27, p<0.0001,
Dunnett’s multiple comparisons test, Figure 3.5A).
IMCs encompassing combinations of the 6 signature mutations were generated
to test their effect on viral replication. Clones were generated using a novel TF SHIV
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backbone, 3C, which contains deletions in the tat and gp41 env reading frames that
were selected for in vivo in RM infected with various TF SHIVs. The 3C backbone
demonstrated a modest fitness advantage in vitro compared to the dCT backbone
previously used for TF SHIV design84 (data not shown).
Clones were named according to the number of signature mutations present
compared to the TF (see Figure 3.5B legend). Several clones (4MA, 5MA, and 5MB)
encoded combinations of mutations seen in vivo (Figures 3.1, 3.2, and 3.3). The
remaining clones (4MB, 3MA-3MD) encoded individual reversions to assess the
contribution of a particular signature mutation to viral fitness in the context of other
mutations. Figure 3.5B shows a representative experiment testing the combination
clones against the TF. By 3 DPI, enhanced replication compared to the TF was
detectable, with all combination clones except for 3MA exhibiting a 3.0-16.6-fold
increase in p27 antigen. The increased levels of replication persisted through later
timepoints, though some replication curves appear dampened by loss of activated target
cells.
When tested in 2-3 independent experiments of mixed/single RM donor CD4 T
cells, almost all of the CH505 combination clones replicated substantially better than the
parental TF SHIV (median = 8.1 to 17.1-fold increase in p27 across 2-3 independent
experiments, Figure 3.5B), with the exception of clone 3MA, which replicated similarly to
the TF (median = 0.2-fold decrease in p27). Although 3 combination clones exhibited
significant increases in replicative capacity compared to the TF across all 3 experiments
(5MB, 3MB, and 3MD, p<0.05, Dunnett’s multiple comparisons test), a clearly dominant
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clone amongst those tested in any individual experiment was not identified, as the best
replicating virus varied depending on rhesus donor.
While mutations in isolation did not significantly affect virus replication in vitro,
combination clones replicated robustly (Figure 3.5A and B), suggesting that there is an
additive or synergistic effect of signature mutations on viral replicative capacity. Of note,
although the V255I signature mutation was consistently deleterious to viral replication
when introduced in isolation to the parental TF Env, when added in the context of the
other mutations that arose simultaneously in vivo in Study 3 (K302N, Y330H, N334S,
H417R), the resultant clone 5MA, demonstrated enhanced virus replication (Figure 3.5A
and B).

In vivo competition of candidate SHIV.CH505 combination clones
The sequence analysis and vitro studies described earlier, while informative, are
not able to determine which multiple competing factors are most important for viral
fitness in vivo; these factors include, but are not limited to, ability to efficiently enter
rhesus cells, intrinsic replicative capacity, and ability to evade autologous neutralizing
antibody (nAb) and other innate and adaptive immune responses. We performed an in
vivo competition experiment using a lower-dose inoculum to enable competition between
viral variants during critical timepoints in early infection. We defined this period as 1-4
WPI, as the effects of replication differences would most evident at the earliest
timepoints post-infection when the virus is expanding exponentially with ample cellular
targets; in HIV-1 infection, it takes approximately 4 weeks for the nadir VL to be reached
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in acutely HIV-infected individuals reflecting an exhaustion of target cells and resolution
of peak viremia128 . Further, using early timepoints as a point of comparison would
minimize the effect of adaptive immune responses on virus selection as much as
possible. A second goal of this experiment was to determine the extent to which in vitro
studies of fitness (Figure 3.5) predict in vivo viral fitness.
Three outbred RM were infected with 10 ng of each of 8 candidate CH505 clones
(Figure 3.6A, left) and followed longitudinally. All animals became productively infected
with peak VL ranging from 104-5 c/ml (Figure 3.6B). Of note, as sampling was only
performed at 1, 2, and 4 WPI, it is likely that the peak VL measurement was not captured
with this sampling strategy. In all 3 RM, viremia was maintained above 102 c/ml through
48 WPI, with set point VLs ranging from 103-5 c/ml between 32 and 48 WPI.
To identify with great sensitivity which signature mutant best competed in vivo, a
deep sequencing strategy with amplicons including the 500 nt region in Env
encompassing all candidate mutations was employed using the Ilumina platform (Figure
3.6A). Sequences from plasma virus at 1, 2, and 4 WPI were generated (Figure 3.6A).
As our deep sequencing strategy requires a bulk amplification step, we performed
limited SGS for selected early time points (W1, W2) in parallel to determine the
frequency of in vitro versus in vivo recombinants; we did not identify any in vivo
recombinants using SGS (data not shown). Sequences from 1 WPI demonstrated that all
8 variants been transmitted and led to productive replication to all 3 RM (Figure 3.6A).
The frequencies of other CH505 variants began to wane at 2 WPI, and by 4 WPI,
variants containing 5MA signature mutations dramatically outcompeted all others,
comprising 76-99% of circulating viruses.
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CH505 signature mutations alter Env conformation
Viruses that circulate in HIV+ individuals encode Envs are predominantly Tier 2
and have been adapted to evade nAbs via several mechanisms, including
conformational masking, glycan shielding and epitope variation, leading to a closed Env
that is not easily accessible to the autologous Ab response52. Autologous antibodies
overwhelmingly target immunodominant regions of Env such as V3 and gp41 that
typically elicit poorly or non-neutralizing antibodies129,130.
Many laboratory-adapted viruses, which replicate well in vitro, exhibit altered and
non-native Env conformation as a result of the lack of Ab pressure in vitro, differentiating
them from primary HIV-1 isolates52. We assessed if and how these mutations altered the
closed nature of the primary CH505 Env due to signature mutations being located in or
proximal to the rhCD4 and CCR5 binding sites. We tested the sensitivity of the panel of
8 combination clones to monoclonal (m)Abs 3869, which targets linear V3 peptides and
preferentially binds Tier 1 viruses131 and 17B, which preferentially binds open CD4bound Envs that express a non-native conformation132 (Figure 3.7A and B).
Clones 4MA, 5MA, and 5MB exhibited combinations of mutations seen in vivo, while
the remaining clones (4MB, 3MA-3MD) were missing at least one mutation that emerged
in vivo in all 3 RM studies by design. While most combination clones did not exhibit
substantially altered Env conformation (<50% neutralization of virus at a maximum mAb
concentration of 10 mg/ml), there were a few exceptions, namely clones 3MB and 3MC,
which contained combinations of mutations that were only seen in Studies 1-3 in the
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context of additional mutations. Clones 3MB and 3MC had increased sensitivity to both
3869 and 17B compared to the TF (70-81 versus 0% neutralization, respectively, Figure
3.7A and B), implying that they bear more resemblance to non-Tier 2 or lab-adapted
HIV-1 isolates than the other CH505 combination clones.
Clone 4MA appeared to be modestly more sensitive to both 17B and 3869, although
the mean neutralization percentage across 4 independent experiments did not reach the
50% threshold. In summary, these data suggest that introduction of signature mutations
into the CH505 Env can lead to altered protein conformation. These results also suggest
that encoding combinations of mutations observed in vivo in the context of the primary
CH505 Env results in a closed Env conformation. Taken together, these results suggest
that 5MA emerged as the leading candidate in vivo due to its combination of increased
intrinsic replicative capacity and closed Env conformation. These results also provide a
rationale as to why combination clones that encode a more open Env conformation
despite demonstrating robust in vitro replication (3MB, 3MC) were not selected for in
vivo.

In vivo competition of CH505adapted versus CH505.TF
To confirm and quantify the in vivo fitness of the variant, 5MA, which had
outcompeted all other CH505 variants in Study 4, we performed a more direct in vivo
competition experiment between this variant and the parental wildtype (WT)
SHIV.CH505 (Study 5). Four RM were inoculated with a virus mixture containing equal
amounts of TF and 5MA viruses as determined via p27 antigen measurement. 2 RM
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(T276 and T277) were intravenously challenged with a lower dose inoculum (15 ng of
each variant) and 2 RM (T278 and T279) were intravenously challenged with a higher
dose inoculum (150 ng of each variant, Figure 3.8A, left). All RM became productively
infected with peak VL of 105-6 c/ml at 1.5-2 WPI in all 4 RM (Figure 3.8B). In all 3 RM,
viremia was maintained above 103 c/ml through 24 WPI, with set point VLs ranging from
103-5 c/ml at the most recent timepoint (24 WPI).
Deep sequencing over the region between the 5 signature mutations revealed
that both variants were transmitted to all 4 RM (Figure 3.8A, right). At 1 WPI, variants
containing 5MA mutations made up 47-79% in all 4 RM; the proportion of viruses
containing 5MA mutations increased to 57-88% by 2 WPI in all animals. At 4 WPI,
variants containing 5MA signature mutations dramatically outcompeted the TF,
comprising 93-95% of all circulating viruses in all 4 RM.
Interestingly, differences in VL between RM that were challenged with high
versus low VL became detectable beginning at 4 WPI. The 2 RM that received the lowdose inoculum exhibited VL that were 9-27-fold higher (mean) at 4-24 WPI than in RM
that received the higher dose inoculum. Further, the proportion of variants containing
5MA mutations was modestly larger in low-dose (64-79%) versus high-dose inoculum
(47-60%) RM at 1 WPI.

CH505.TF and 5MA have conserved Env conformations
Given that Studies 4 and 5 had identified 5MA as a leading candidate, we
performed a more thorough characterization of potential differences in antigenic
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conformation in 5MA versus TF.CH505 (Table 3.1). The antigenic conformation of 5MA
was shown to be similar, although not quite identical (<4-fold difference in IC50)
compared to CH505.TF when tested for neutralization sensitivity to a panel of bNAbs
targeting conserved Env epitopes, including the CD4 binding site (VRC01, 3BNC117),
the V2 apex (PGT145), and the gp120/gp41 interface/membrane-proximate external
region (4E10, Table 3.1). The exception to this result was 5MA’s increased sensitivity to
PGT121, which targets the V3 glycan supersite. The N334S mutation present in clone
5MA introduces an N-linked glycosylation site (NLGS) at residue 332 and subsequently
enables recognition by PGT121.
A few minor, but not unexpected, differences in sensitivity to CD4 and V2 bNAbs,
however, were noted. 5MA demonstrated modestly decreased (3-4-fold) sensitivity to
CD4 bNabs and modestly increased (3-fold) sensitivity to the V2 apex bNAb PGT145. A
previous study found that Env residue 255 substitution results in decreased binding of
HIV-1 isolates to huCD4 and increased sensitivity to V2 apex bNAbs 124; thus, the V255I
mutation likely mediates the differential sensitivity of 5MA to both types of bNAbs.
Notably, both 5MA and TF Envs were completely resistant to mAbs 3869 and 17B
(Figure 5), suggesting that 5MA has a similarly closed Env conformation.

Replication of CH505 clone 5MA in isolation
To characterize the in vivo properties and fitness of clone 5MA in isolation, 4
outbred RM (Study 6) were IV infected with a virus stock containing 340 ng of 5MA and
followed longitudinally (Figure 3.9). Peak VLs ranged between 10 6-7 c/ml, while set point
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VLs ranged between 103-5 c/ml at 12 WPI, with no incidence of spontaneous viremic
control. This experiment is ongoing.

CH505 clones containing signature mutations have differential entry into cells
expressing rhCD4 and CCR5
To assess the mechanism of enhanced replication, we asked whether more
facile entry was the predominant cause. This is biologically plausible, as mutations lie
within or proximal to CD4 and coreceptor (CoR) binding sites. To assess the contribution
of signature mutations to differences in cell entry, ZB5 cells, which stably express rhesus
CD4 and CCR584 and encode a luciferase reporter, were infected with the 14 point and
combination mutation clones described in Figure 3.5. An additional clone with the N130D
mutation in isolation was included as a comparator.
Clones containing signature mutations in isolation were tested against the TF;
percent entry was normalized to the TF (shown as a dotted line in Figure 3.10A and B).
4 signature mutations (N130D, Y330H, N334S, H417R) appeared to minimally affect
entry into ZB5 cells in isolation (Figure 3.10A). 2 mutations (V255I and K302N) were
significantly deleterious to viral entry (59 and 49% decrease in entry, respectively,
p<0.05, Dunnett’s multiple comparisons test, Figure 3.10A).
Combination clones were also tested against the TF (Figure 10B). 2 clones (5MA
and 3MD) demonstrated significantly enhanced entry compared to the TF (>64%
increase, p<0.0001, Dunnett’s multiple comparisons test). A third clone (5MB) also
demonstrated significantly increased entry (>45% increase, p<0.001, Dunnett’s multiple
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comparisons test), albeit to a lesser extent. These findings suggest that entry is a
significant contributor to the enhanced replication seen in vitro and in vivo for 5MA.
These results, however, do not completely explain why 5MA emerged as the leading
candidate in vivo given that 5MB and 3MD also enter rhesus cells efficiently, reinforcing
the complex combinatorial contributions of multiple mutations to SHIV.CH505 fitness.
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Figure 3.1. Identification of a signature of enhanced SHIV.CH505 VL kinetics
(Study 1). A. Amino acid highlighter plots showing single genome env sequences from
SHIV.CH505-infected RM 6069, 6070, and 6072 (Study 1) at 4, 10, and 20 WPI. Nonsynonymous substitutions compared to the TF sequence are indicated by a red line and
deletions are shown as a black line. Each horizontal line shows one single genome
sequence. 6 signature mutations arose de novo in all 3 RM by 20 WPI. N130D is shown
in blue, while N279D, K302N, Y330H, N334S and H417R, are indicated in purple. B.
Summary table showing frequency of Env signature mutations in each RM over time.
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Figure 3.2. Confirmation of a signature of enhanced SHIV.CH505 viral kinetics
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Figure 3.3. CH505 passage 1 and 2 (Study 3). A, left. RM 5695 was inoculated with a
mixture of early plasmas from RM 6069, 6070, and 6072. RM 5181 was inoculated with
a mixture of early plasmas from RM 5181. A, right. Viral kinetics for RM 5695 (top) and
5181 (bottom). Euthanasia due to AIDS progression is indicated by a black cross. B.
Amino acid highlighter plots showing longitudinal env sequences from P1 and P2 RM
5695 and 5181. 5 signature Env mutations (N279D, K302N, Y330H, N334S and H417R)
that were previously identified in Figure 3.1 and 3.2 are indicated in purple. N130D is
indicated in blue. V255I, a novel signature mutation, is shown in green. C. Summary
table showing frequency of Env signature mutations in each RM over time.
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Discussion
Given the historical success of using serial passage to develop and improve SHIVs,
we utilized this method to augment the viral kinetics of SHIV.CH505 to enhance its
suitability for a SHIV-macaque model of HIV-1 infection. Several factors necessary for
both in vitro and in vivo replication and persistence, such as efficiency of entry into cells
expressing rhesus CD4 and CCR5, evasion of the host immune response, and
enhancement of infectivity in vitro and in vivo, must be balanced in order for a virus to
become adapted to its host. In addition, a suitable virus would need to encode an Env
with a closed and conformationally masked conformation to aid in successful host
immune evasion.
Here, we describe the generation of a minimally adapted SHIV.CH505 encoding 5
mutations. We used the framework underlying serial passage to generate an vivo
competition experiment where the most fit viral variant would outcompete in its host; this
work is the first to do so, to our knowledge. First, we identified a genetic signature of 4-6
mutations in gp120 Env that were associated with sustained set point viremia in 8
SHIV.CH505-infected RM in 2 independent studies (Figures 3.1 and 3.2). In the setting
of a limited passage experiment in 2 RM, a similar mutational signature was identified;
these mutations arose and went to fixation earlier than in a setting where they had to
arise de novo and were associated with enhanced VL kinetics over time (Figure 3.3). An
additional signature mutation (V255I) was identified in both Study 3 RM (Figure 3.3).
Structural modeling (Figure 3.4) suggested that 6 of 7 identified signature mutations
are located in sites that interact with or are adjacent to human and/or rhesus CD4 and
CCR5-binding sites. It is important to note that there are some structural and functional
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differences between the rhesus and human CD4 and CCR5 molecules116,133. Functional
mapping studies of all non-synonymous substitutions in rhesus versus human CD4,
however, have revealed that a single mutation at the N-terminus in D1 of rhesus CD4,
which binds gp120 Env, mediates differential binding to HIV-1 Env116, as the remaining
11 substitutions in D1 had minimal effects on HIV-1 Env binding. As Env 375 substitution
results in similar binding and entry into rhesus cells, it is likely that the modest sequence
variation between rhesus and human CD4 does not result in significant functional
differences between the 2 molecules84. A previous report found that HIV-1 Envs bind to
rhesus and human CCR5 in a conserved manner, likely on account of high sequence
conservation (98%) between both molecules133. Further, the 3 non-synonymous
substitutions in rhesus versus human CCR5 do not restrict viral entry of primary HIV-1
isolates, as tested viruses were able to comparably infect cells that express CCR5 from
either species133.
N130D, an additional signature mutation which was excluded from further analysis
due to the reasons described earlier, most likely arose due to early autologous nAb
responses targeting the V1 region in Env, which has been previously reported in HIV-1
infection and was shown to be conserved in SHIV.CH505-infected macaques134,135,119.
Further, N130D arose in the CH505 source patient at 52 weeks post-infection118.
X-ray crystallography, cryo-EM, and mutagenesis studies summarized here shed
further light into the putative role of each mutation. N302 is highly conserved across 96%
of HIV-1 isolates66. Further, a recent cryo-EM study of the gp120 Env ectodomain in
complex with human CD4 and CCR5 identified N302 as a CCR5 contact residue 122. The
impact of Y330H on HIV-1 or SHIV viral fitness is currently unknown. H330, however, is
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conserved in 70% of HIV-1 isolates66, as is S334 (75% conservation)66. As a result,
K302N, Y330H and N334S are likely viral fitness reversions to Group M consensus.
Multiple mutagenesis studies have identified residue 417 as a mediator of binding and
entry into CD4-expressing target cells126,127. Of note, the residue of choice in HIV-1
appears to be P, with 85% conservation at this site across all sequenced global isolates
(LANL 2018 Compendium). It is therefore likely that H417R is a either a rhesus CD4specific adaptation or a result of the conserved nAb response in both the CH505 source
patient and SHIV.CH505-infected RM and incidentally modulates viral fitness 119.
Previous structural modeling found that Env residue 255 is located within 4Å of the
CD4 binding site84. A recent report124 found that the V255M substitution, which is
structurally similar to the V255I substitution, altered the Env conformation of several HIV1 isolates by reducing the ability of Env to bind CD4, resulting in increased sensitivity to
apex-targeting bNAbs that preferentially recognize closed Envs. Residue 279 is a known
CD4 contact residue123; in HIV-1 isolates, the N279D mutation conferred resistance to
CD4 binding site-directed Abs125.
A recent study found that Env mutation A281T/V frequently arises in the setting of in
vivo SHIV adaptation in RM and confers a modest virus fitness advantage in vitro 136. In
the parental SHIV.CH505, the amino acid at residue 281 is the “optimized” V. Notably,
the inverse substitution (V281A) arose in one Study 1 RM, 6070, with 17% prevalence at
20 WPI, but not in any other Study 1, 2, or 3 RM; in these RM, the T and V alleles were
retained at residue 281.
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CH505 clones containing signature mutations in isolation demonstrated a marked
increase in intrinsic replicative capacity in comparison to the TF in primary rhesus CD4 T
cells (Figure 3.5A). 7 of 8 candidate clones containing combinations of signature
mutations replicated substantially more robustly than the TF in vitro (3.5B). Clone 5MA,
which contains 5 AA changes compared to CH505.TF, emerged as the front runner in
both competition in vivo studies (Study 4 and 5), rapidly outcompeting other candidate
combination clones (Figure 3.7) as well as CH505.TF by 4 WPI (Figure 3.8). The
dramatic in vivo selection of 5MA is likely attributable to several factors, including
increased in vitro infectivity in primary rhesus CD4 T cells (Figure 3.5), retention of
native Env conformation, and Tier 2 neutralization sensitivity (Figure 3.6 and Table 3.1).
5MA was one of several engineered clones that encompassed a set of signature
mutations that were maintained in vivo (Figures 3.3, 3.6, and 3.8). The enhanced
infectivity of 5MA in vitro is mediated at least in part by enhanced entry into rhesus CD4
and CCR5-expressing cells compared to the TF (Figure 3.10). Accordingly, the infectivity
per particle ratio of 5MA was found to be 2.31-fold and 3.53-fold greater when titrated on
TZM-bl and primary rhesus CD4 T cells, respectively, compared to the TF (data not
shown).
Taken together, results from in vitro studies were supportive, although not entirely
predictive, of in vivo studies, as combination clones 5MB and 3MD also demonstrated
enhanced in vitro replication (Figure 3.5), significantly enhanced entry into ZB5 cells
(Figure 3.10), and retained closed Env conformation (Figure 3.7), but nonetheless did
not outcompete other clones in vivo at key early time points in Study 4 (Figure 3.6).
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In vitro studies suggest that V255I and N279D contribute to enhanced viral
replicative capacity in vitro (Figure 3.5B) and modulate Env protein conformation in a
similar manner when compared to clone 4MA (Figure 3.7). Clone 4MA contains 4 of 5
substitutions present in clone 5MA and encoded a modestly more open Env
conformation (Figure 3.6). Notably, despite detection of all 6 CH505 combination clones
in all Study 4 RM at 1 WPI, which presented ample opportunity for in vivo recombination,
a combination clone with all 6 signature mutations (V255I, N279D, K302N, Y330H,
N334S, H417R) was not selected for. These results suggest that substitutions V255I and
N279D have potentially redundant roles in the context of other signature mutations and
that 5MA, which encodes the V255I mutation, appears to be more fit in vivo.
The V255I mutation likely arose later in Study 3 RM 5695 and was not selected for in
Study 1 and 2 RM due to its poor intrinsic replicative capacity in isolation (Figure 3.5A).
Based on these data, it is likely that V255I requires compensatory fitness mutations (i.e.
K302N, Y330H, N334S, H417R) to arise in vivo. A virus engineered to encode these 4
mutations in addition to V255I, however, is sufficiently fit to replicate robustly in vitro
(Figure 3.5B) and outcompete all other tested CH505 variants in vivo (Figure 3.6 and 8).
V255I did not arise in the CH505 source patient118, suggesting that it may be a rhesus
CD4-specific adaptation.
The contribution of the signature mutations described here to SHIV.CH505 viral
fitness may not necessarily be generalizable to other SHIVs. Nonetheless, this study
serves as a conceptual framework suitable for adapting other SHIVs that replicate
suboptimally in RM. The approach delineated in this study echoes previous work
described by Sodroski and colleagues67,68, which utilized a similar approach to augment
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the pathogenesis of SHIV 89.6 and subsequently dissect the mechanisms responsible
for enhanced infectivity and pathogenesis.
These results suggest that the role of mutations that conferred enhanced fitness in
this context can be broadly defined as falling into 2 distinct subtypes: 1) increased
efficiency of utilization of CD4 and CCR5 via entry or other mechanisms or 2) fitness
reversions to Group M consensus. These results, like others 68,84 pinpoint efficient viral
entry as a mediator of increased fitness in rhesus-adapted SHIVs, a particularly
important consideration given that the structural and regulatory elements of SHIVs
outside of Env are SIVmac-derived and therefore already are sufficiently adapted to the
rhesus macaque. Viral entry, however, is likely not the only contributing factor, as it does
not explain why 5MB or 3MD were not selected for in vivo despite also showing
increased entry into rhesus cells.
We acknowledge several limitations associated with our studies. First, the effect of
CH505 signature mutations on other HIV-1 Envs was not evaluated. As a result, it is
possible that signature mutations are context-dependent and cannot be used to augment
other SHIVs. Alternatively, signature mutations may be generally advantageous for viral
fitness in SHIVs, which would require additional investigation.
In addition, the temporality of host immune pressures following infection, which have
been shown to emerge as early as 1.5-4 WPI in HIV27,28 and SHIV85 infection, preclude
our ability to decisively state that variants with signature mutations were selected for in
Studies 1-5 solely due to a viral fitness advantage, as it is possible that host neutralizing
antibody and/or CD8 T cell responses exerted significant selection pressure on the virus
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population. As discussed earlier, since viral fitness can be considered to encompass
both intrinsic viral replicative capacity as well as the ability of the virus to escape
adaptive immune pressures in its host, we do not find this caveat to be a significant
confounding factor of this study.
There are several additional limitations associated with the in vivo passage studies
described in Figure 3.3, including the use of plasma-derived virus to infect RM 5695 and
5181, as antibodies in plasma, if still viable, could potentially neutralize virus from earlier
time points prior to inoculation. A second limitation is that RM 5695 and 5181 were
infected with a viral swarm as opposed to a single IMC, which could have contributed to
enhanced viral kinetics due to increased viral diversity at the time of virus acquisition.
This increased inoculum diversity could have contributed to attenuated adaptive immune
responses in these RM, resulting in the unusually enhanced VL seen in Study 3 RM.
Nonetheless, given that we identified a similar mutational signature in 10 other RM in 2
additional studies (Figures 3.1 and 3.2), it is likely that these factors did not significantly
confound our results.
We employed a deep sequencing approach to generate the results described in
Figures 3.6 and 3.8 due to the expense and labor involved in SGS as well as the
increased sensitivity of deep sequencing in detecting minority variants. One major
limitation of deep sequencing, however, is that it precludes our ability to differentiate
between in vitro and in vivo error. Accordingly, we detected recombinant variants even in
the Study 4 inoculum, despite sequencing every CH505 clone that comprised the
inoculum in its entirety and not identifying any recombinants. Further, we stratified the
recombinants according to numbers of mutations present and found that the vast
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majority of recombinants contained 4 of 5 signature mutations and were missing either
V255I and H417R, suggesting that these sites were inclusive of common break points.
This finding is inconsistent with a pattern of random in vitro recombination. Limited SGS
(n = 9-30 sequences), which prevents in vitro recombination altogether, was performed
at 1 and 2 WPI for all Study 4 RM and 2 of 4 Study 5 RM; no recombinants were
identified in any of the sequenced samples, adding further evidence that most, if not all,
of the recombination observed in the samples sequenced in Figures 3.6 and 3.8 was
artefactual in nature (data not shown). These limitations, however, are unlikely to
significantly affect the interpretation of the results presented here.
Our results suggest that clone 5MA, which we have termed SHIV.CH505.v2,
retains the very properties that make it valuable, including conserved antigenicity and
Tier 2 neutralization sensitivity, yet confers enhanced longitudinal enhanced viral
kinetics, resulting in a promising model for HIV-1 latency and cure research.
Applications for this novel reagent include both vaccine and bNAb-based studies as well
as latency and cure studies. Efforts to assess the suitability of SHIV.CH505.v2 for
latency and cure research via measurement of VL kinetics and reservoir before, during,
and after cART administration, are ongoing (Figure 3.9). We conclude that
SHIV.CH505.v2 has potential as an important new NHP reagent with broad applications
for HIV research.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
Summary
A robust simian-human immunodeficiency virus (SHIV)-macaque model of
latency is critical to investigate eradicative and suppressive strategies that target HIV-1
Env. TF SHIVs are engineered to mitigate issues associated with previous iterations of
SHIVs. Most importantly, TF SHIVs encode HIV Envs that are biologically relevant to
and representative of isolates that are transmitted to and circulate in PLWH.
Prior to this work, the reservoir biology and pathogenesis of infection in RM both
off and on cART had not been characterized for any iteration of SHIV, including those
developed by our group. Here, for the first time, I evaluated TF SHIVs for their suitability
for HIV-1 latency and cure research (Chapter 2). In this chapter, I found that in general,
TF SHIVs recapitulate key aspects of HIV-1 reservoir biology and persistence, with
several caveats. The findings described in Chapter 2 expand the field’s knowledge of the
benefits and limitations of SHIVs as a model for HIV latency and cure research and
enable the design of more rigorous preclinical studies, where results could be more
easily translatable to clinical trials.
The theory of serial passage builds upon studies examining the factors
associated with cross-species transmission, in which adaptive and innate immune
pressures, including intrinsic antiviral restriction factors, antibodies, and CD8 T cell
responses, among others, exert significant selective pressure upon a pathogen
introduced into a novel host. Thus, a pathogen must be able to evade all of these
immune defenses to adapt fully to a novel host. Serial passage, which involves infecting
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RM with diverse SHIV variants and enabling the host to choose the most fit virus, has
been historically successful in improving SHIV kinetics. The work described in Chapter 3
is the first to utilize an approach that distills this concept to a more reductive form. In
Chapter 3, I describe how the concept of serial passage can be repurposed to engineer
IMCs that are representative of viral mutations associated with fitness that are selected
for in vivo in multiple RM, including in a limited passage setting.
I generated 8 SHIV.CH505 infectious molecular clones (IMCs) that were
generally representative of the virus populations circulating in SHIV.CH505-infected RM
and were shown to have desirable characteristics for a NHP model of HIV-1 infection in
vitro. Out of these 8 IMCs, 5MA alone dramatically outcompeted others by 4 weeks postinfection in 7 outbred RM. I found that the enhanced fitness in vitro and in vivo of the
leading candidate clone, 5MA, was at least partly explained by its ability enter target
cells more efficiently than TF.CH505 (Chapter 3).
Throughout the history of SHIV development, the rationale behind spontaneous
viremic control of SHIVs to below 102-3 c/ml is of great interest, but poorly elucidated.
Although the work presented here does not definitively identify the mechanisms
responsible for spontaneous control, it suggests that shifting the SHIV-host balance to
the side of the virus by developing SHIVs with enhanced replicative capacity can
mitigate this issue. The mechanisms underpinning the enhanced persistence of
SHIV.CH505.v2 are likely mediated by a combination of enhanced entry, binding to
target cell receptor and coreceptor, and/or fusogenicity, consistent with the mechanistic
studies of SHIV 89.6 described by Sodroski and colleagues67,68. This work is the first to
use an analogous approach to dissect the mechanisms responsible for the enhanced
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fitness of a CCR5-tropic SHIV. Thus, the studies presented here could provide an
experimental framework for augmenting other promising SHIVs that demonstrate
variable persistence in RM.

Future Directions
Reservoir biology and viral persistence in TF SHIV-infected RM
Given that there are an extensive number of well-powered SIVmac studies, it will
be important to validate the findings observed for TF SHIVs 191859 and CH848 in larger
cohorts of RM to better assist investigators deciding between the SHIV and SIVmac
models. Higher-powered studies will be particularly important given the high incidence of
spontaneous control (3 of 4 animals) in the SHIV.CH848-infected RM described in
Chapter 2. Further, given that the duration of cART in humans is often years to
decades40, it will be important to repeat these studies in a setting where longer term
cART (>24 weeks) can be administered. Long-term administration of cART would allow
the opportunity to potentially identify reservoir decay in longer lived cellular reservoirs
such as resting memory CD4 T cells using methods such as quantitative viral outgrowth
assays (QVOA)40 or quantification of intact proviral DNA (IPDA)137 which have been
robustly validated in HIV-1 infection40. In addition, quantification of ca-DNA and RNA in
tissues from the central nervous system43 and other possible anatomical reservoirs in
HIV-1 infection will be necessary to validate the robustness of this model for HIV latency
and cure research.
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Further, it will be important to plan studies that result in recovery of enough viable
PBMC and LNMC to conduct QVOAs. This would enable quantification of the number of
ca-DNA and ca-RNA+ cells that harbor replication-competent vs. incompetent virus. In
addition, we did not sample lymphoid tissues from the SHIV.CH848-infected RM
described in Chapter 3. It would have perhaps been informative to assess if the lack of
persistent viremia in 3 of 4 SHIV.CH848-infected RM post-rebound was linked to
decreased reservoir seeding in lymphoid tissues compared to RM KK54, which
maintained persistent post-rebound viremia. At least one line of evidence suggests that
this question merits further investigation: the magnitude of virus dissemination, as
assessed by ca-DNA and RNA quantification, was substantially higher in tissues from
SHIV.D-infected progressor RM EJ94 and DE33 in comparison to RM FT42, which
spontaneously controlled viremia at 42 WPI and did not progress to AIDS (Figure 2.4),
In addition, due to an inadequate number of viable cells, we were not able to sort
LNMC into all T cell subsets, including Tscm, Tem, etc. and were not able to sort LNMC
from SHIV.D-infected RM by subset. It would be helpful to characterize the LNMC and
PBMC populations in RM infected with other TF SHIVs, as the characterization of T cell
subsets in 4 RM infected with a single TF SHIV is inadequate to fully characterize SHIV
reservoir biology and persistence in both PBMC and tissues.

Defining the mechanisms associated with enhanced SHIV.CH505.v2 viral fitness
Given the role of signature mutations in SHIV.CH505.v2 viral fitness, it will helpful
to fully probe the mechanisms by which signature mutations confer enhanced in vivo and
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in vitro fitness. The work presented here addresses the contribution of signature
mutations to viral entry. This was assessed via a single-round entry and infection assay
with ZB5 cells, which stably express rhesus CD4 and CCR5. The ZB5 assay identified
entry as an important component of replication differences associated with some, but not
all, mutations. This assay, however, does not address myriad other mechanisms that
could be responsible for the increased infectivity of candidate SHIV.CH505 clones.
Future work should examine other factors that can modulate enhanced viral fitness,
including syncytium-forming abilities as described by Sodroski and colleagues68 in the
context of SHIV 89.6 clone KB9. A clone with enhanced fusogenicity would be predicted
to result in greater cytopathic effects, which could be tested via a controlled syncytium
formation assay where Env-expressing SHIV.CH505 clones would be co-cultured with
target CEMx174 cells sourced from the NIH AIDS Reagent Program. The number of
cells that have formed syncytia could be counted using microscopy after 6 hours, which
would help determine if signature mutations affect viral fusogenicity.
Further, it would be worthwhile to test whether signature mutations affect affinity
for and binding to rhesus CD4. This could be determined using TZM-bl neutralization
assays, where soluble rhesus e-CD4-Ig could be serially diluted and tested against
SHIV.CH505 clones instead of bNAbs or plasma as described in 84. In addition, it would
be helpful to assess if introduction of signature mutations alter CH505 Env affinity and
binding to the rhesus CCR5 molecule, which could be assessed using titration of soluble
rhesus CCR5 or the titration of a CCR5 inhibitor, such as maraviroc, which binds to
human as well as rhesus CCR5, using the modified TZM-bl neutralization assay
described above138. All of these possibilities will need to be evaluated in order to fully
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dissect the mechanisms responsible for the increased replication of 5MA in vivo and in
vitro, in addition to enhanced entry.

Validating SHIV.CH505.v2 for latency and cure research
While a pilot study that aims to validate SHIV.CH505.v2, for latency and cure
research is ongoing, it will be important to 1) carefully characterize SHIV.CH505.v2
reservoir biology and immunopathogenesis in these RM and 2) compare and contrast
this virus with its predecessor, SHIV.CH505.TF, as well as other TF SHIVs and HIV-1.
First, extensively sampling both PBMC and lymphoid tissues and assessing the extent of
CD4 T cell depletion and virus dissemination as determined via ca-DNA and RNA
quantification upon necropsy would be necessary. Second, sequencing the virus
population using SGS at pre-cART and post-ATI timepoints and comparing viral diversity
measures, including pairwise diversity and clonality, to other TF SHIVs and HIV-1 would
be beneficial. Further, given an appropriate quantity of viable cells, it would be useful to
assess what percentage of the viral reservoir in both blood and tissues is replication
competent, which could be determined via QVOA or IPDA. Finally, the detection of viral
rebound post-ATI would serve as the most definitive proof that a persistent viral reservoir
is seeded during SHIV.CH505.v2 infection, thus validating this model for HIV-1 latency
and cure research.
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Testing therapeutics, cure strategies, and vaccines in TF SHIV-infected RM
TF SHIVs are highly suitable for evaluation of Env-targeting agents, as they
encode Envs that are more relevant to TF and circulating variants than any previous
iteration of SHIV. TF SHIVs are as sensitive to available bNAbs as their parental HIV-1
isolates; further, the antigenic profiles of TF SHIVs have been extensively characterized,
in contrast to some SHIVs currently in use. SHIV 162P3 is resistant to many classes of
bNAbs including those targeting various conserved epitopes, such as V1V2, MPER, and
the CD4 binding site, among others73. The antigenic conformation of SHIV AD8EO has
not been extensively characterized. However, SHIV AD8E0 is far more resistant to a
number of bNAbs than the parental AD8 Env139.
A study by Boyd et al.139 determined that adapting SHIVs AD8EO and 162P3 to
macaque CD4 resulted in substantial conformational changes, exposing epitopes that
are masked in the parental Envs and disrupting key quaternary Env epitopes; the design
of TF SHIVs circumvents this non-trivial issue. In addition, our group has generated >20
TF SHIVs encoding various HIV-1 Env clades, which offers a unique opportunity to test
these interventions in an NHP model that can recapitulate global HIV-1 diversity. Given
that TF SHIVs have been recently validated for HIV-1 latency and cure research 86, it will
be important to assess if prophylactic administration of next-generation bNAbs can 1)
prevent TF SHIV acquisition and 2) delay viral rebound in the context of ATI.

123

Our group is currently evaluating the efficacy of a CD4 binding site bNAb,
VRC07, in delaying viral rebound in SHIV.D-infected RM upon ATI. However, more
studies will be required to validate TF SHIVS for these applications. Further, TF SHIVs
offer a unique opportunity to dissect the mechanisms responsible for discordant results
in preclinical studies that utilized SHIVs 162P3 and AD8 to evaluate bNAb therapy and
clinical trials, where bNAbs did not elicit the same striking effects reported in NHP
studies, including augmenting CD8 T cell responses and delaying post-ATI viral rebound
indefinitely56,57. Such studies are likely to assist investigators in developing HIV-1
therapeutics that are more likely to transition successfully from preclinical to clinical
development.
In a previous study, a regimen consisting of a bNAb administered in tandem with
the latency reversal agent (LRA) GS-9620 significantly delayed rebound in SHIV 162P3infected RM following ATI56. LRAS are engineered to reactivate infected cells from
latency, thus enabling immune targeting and clearance of infected cells. LRAs have
become a cornerstone of HIV cure strategies; numerous classes of LRAs are currently in
preclinical and clinical development140. While RM infected with SHIVs AD8 and 162P3
have demonstrated viremic suppression on cART and viral rebound upon ATI56,57, the
reservoir biology of these viruses has been incompletely elucidated. The work described
in Chapter 2 suggests that the viral reservoir dynamics and biology of TF SHIV infection
is sufficiently similar to HIV-1 infection to enable evaluation of LRAs with or without
concurrent bNAb administration.
An additional next step would be to test vaccine candidates using TF SHIVs as a
challenge virus. One study performed by Felber and colleagues117 demonstrated a
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significant difference in per exposure SHIV.CH505 acquisition risk in RM co-immunized
with a DNA vaccine and CH505 Env proteins as described in Chapter 3. Studies by
other investigators using BG505 SOSIP141 trimers and other promising vaccine
candidates against autologous TF challenge viruses are ongoing. It will be important to
repeat these studies using heterologous viruses or a mixture of various TF SHIVs from
various clades to assess the efficacy of vaccine candidates in a context most similar to
HIV-1 infection.

Concluding Remarks
The studies described here demonstrate for the first time that TF SHIVs are a
robust NHP model for HIV cure and latency research. Further, this work is the first to
extensively characterize reservoir biology in SHIV-infected RM both off and on cART in
the absence of an intervention. In addition, this work provides an experimental
framework for optimizing SHIVs that persist suboptimally vivo using insights gleaned
from the theory and results of SHIV serial passage. Taken together, the results
presented here underscore the promising role of SHIVs, and TF SHIVs in particular, in
both elucidating mechanisms of HIV pathogenesis, persistence, and reservoir biology
and evaluating interventions, such as vaccines, prophylactics, and therapeutics, in an
increasingly relevant NHP model of HIV infection.
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